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Colorectal cancer is the second most common cause of cancer death in 
Western Europe and North America. Current therapies are largely ineffective and are 
associated with considerable morbidity. Activating mutations in KRAS and BRAF 
genes are frequent in colorectal cancer, especially at later stages of the disease, and 
result in constitutive activity of the MAPK pathway, leading to increased 
proliferation and tumour survival. The MEK1/2 inhibitor AZD6244, that targets the 
MAPK pathway downstream of these mutations, has been tested as novel therapy for 
colorectal cancer. However, clinical trials have been disappointing due to an apparent 
intrinsic and/or acquired resistance to treatment. Mechanisms underlying this 
resistance have been studied using cell lines and tumour xenografts. However, the 
relevance of these data to advanced human colorectal cancer is unclear. 
  One of the difficulties in testing and developing novel therapies for colorectal 
cancer is the lack of representative models of human disease. Thus, the initial aim of 
my PhD was to develop a method to culture human colorectal cancers ex vivo in 
order to use this as a platform for investigating response to AZD6244 and other 
therapies. These studies indicated that regardless of growth conditions, colonic 
tumour explants suffered extensive apoptosis in the first 24h in culture, which limited 
their application in drug response assays. Therefore, as an alternative to long term 
culture of human colorectal explants, I tested the effects of AZD6244 using acute 
treatments. Twenty three fresh colonic tumours were obtained from patients and 
treated for 1h with AZD6244 ex vivo in dose response studies. In all samples, 
MEK1/2 inhibition occurred within 1h of treatment. In one group of particularly 
sensitive tumours, the drug also had a distinct phenotypic effect. In these tumours, I 
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found that the agent induced a dose-dependent decrease in proliferation and increase 
in apoptosis within 1h of treatment. Analysis of markers for this sensitivity indicated 
it was not clearly dependent of the presence of KRAS or BRAF mutations, which 
have previously been shown to confer sensitivity. Other markers of sensitivity / 
resistance were also examined. In addition to studies with AZD6244 alone, I 
examined the combined effects of this agent and aspirin in colon cancer cells lines 
and in tumour explants, with promising results. Whilst the use of fresh patient 
tumour tissue has some technical and logistical challenges, these data suggest that 
such methodologies are worthy of further investigation as a means to examine 
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1.1 - Colorectal Cancer 
Colorectal cancer is the third most commonly diagnosed type of cancer 
worldwide (1) with an incidence of over 1 million reported every year (2). It is the 
third most commonly diagnosed cancer in males and the second in females (3), with 
approximately 80% of patients being diagnosed between the ages of 55 and 85 years 
old (4). Despite advances in surgical techniques and adjunctive therapies the overall 
5-year survival rate is still approximately 50% (5).  
Colorectal cancers develop in a stepwise fashion from normal epithelial 
mucosa to benign tumours or adenomas, and into malignant tumours or carcinomas 
as a result of two major processes: microsatellite instability caused by defective 
DNA mismatch repair or chromosomal instability. The former accounts for 
approximately 15% of colorectal cancers and the latter is responsible for 85% of 
cases (6). Carcinomas have the ability to invade other tissues underlying the 
intestinal epithelium and as a result tumours eventually acquire the capacity to 
migrate to other organs and form metastasis. While the progression from adenomas 
to carcinomas occurs through a period of many years, the development of metastatic 
disease is a much faster process (less than 2 years), and few events are needed for a 
cell population with high invasive potential to acquire the ability to metastasize (7).   
Colorectal cancers are routinely classified according to Dukes and TNM 
systems both of which determine the local extent of the disease. Dukes classification, 
which is based on histopathological information obtained from microscopic 
examination of resected tumours, originally separated tumours into 3 categories: an 
A tumour remained confined to the intestinal wall, a B tumour had spread beyond the 
intestinal wall but had not invaded the lymph nodes, and C tumours had already 
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formed lymph node metastasis. A D category was later on added to indicate the 
presence of distant metastasis (8).  
The TNM (Tumour, Nodes, Metastasis) system includes clinical and 
pathological staging approaches, and as it can be applied to pre-operative evaluation 
of patients provides a more comprehensive classification than the Dukes system. The 
TNM system is also constantly updated to reflect the most recent and robust data. In 
this system, T refers to the extent of the primary tumour at the time of diagnosis, N 
refers to the lymph node status, and M refers to the presence of distant metastatic 
disease. A “p” or “c” used as a prescript designates the pathological or clinical 
determination of the TNM stage, respectively. Tumour stage is usually referred to as 
number I, II, III or IV which represents the TNM information grouped by prognosis. 
A higher number indicates a more aggressive tumour and a worse outcome (9, 10).  
Dukes and TNM staging systems are useful to stratify patients, define 
therapeutic approach and determine prognosis based on tumour morphology and the 
local extent of the disease. However, it is not uncommon that patients with tumours 
with similar characteristics present very different outcomes. Also, some tumours 
present atypical morphologies or lack characteristics essential for classification and 
cannot therefore be placed into a definite category which might result in inaccurate 
diagnosis and consequent inadequate patient care (11). Molecular characterisation 
and staging of tumours based on molecular markers and gene expression signatures, 
together with histopathological characterisation would provide better insight of the 
tumour’s individual properties, and a fundamental tool to define adequate therapeutic 
strategies and accurately predict long term prognosis (12, 13).  
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Despite the use of comprehensive classification systems and recent advances 
in anti-cancer therapies, the outcome of patients with advanced colorectal cancers is 
still very poor. While 90% of those diagnosed with localised tumours survive after 5 
years, the survival rate drops to 67% for those diagnosed with lymph node disease, 
and is dramatically decreased to less then 10% for patients with metastatic tumours 
(14, 15). Currently available colorectal cancer therapies are still largely ineffective 
against the later stages of the disease with metastatic cancers presenting the biggest 
challenge in terms of therapeutic intervention. 
 
1.2 – Current Therapies 
The complex network of events that define colorectal cancer and other 
cancers makes it difficult to design therapies that efficiently eradicate tumours. 
Nevertheless, chemotherapies aimed at invasive colorectal cancers have greatly 
evolved in the past 50 years since the discovery of 5-fluorouracil, the development of 
the cytotoxic agents, oxaliplatin, irinotecan, and capecitabine, and the use of 
combined chemotherapies (16). Recently, targeted therapies using monoclonal 
antibodies such as Bevacizumab (Avastin), Cetuximab (Erbitux) and Panitumumab 
(Vectibix) have been developed.  
Bevacizumab is a humanised monoclonal antibody against vascular 
endothelium growth factor (VEGF), an important pro-angiogenic protein 
overexpressed in tumour cells (17, 18). Inhibiting VEGF results in blood vessel 
regression, and inhibition of formation of new vessels with consequent reduction of 
blood supply and tumour growth (19). Cetuximab is a chimeric IgG1 monoclonal 
antibody and Panitumumab is a fully humanised monoclonal antibody. Both 
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therapies target the epidermal growth factor receptor (EGFR) which is involved in 
cell differentiation, proliferation and survival, migration, angiogenesis and apoptosis 
(17, 20, 21).  
The use of targeted therapies, alone or combined with cytotoxic agents, is still 
somewhat controversial. While some authors claim that it can significantly increase 
the life expectancy of metastatic colorectal cancer patients (19, 22), others suggest 
that treatment with these therapeutic options does not improve progression free 
survival, overall survival and quality of life (21, 23). Also, the outcome of these 
therapies is variable as not all patients respond to treatment, and the mechanisms that 
affect their efficacy are still not fully understood.  
To date no proven biomarkers of efficacy of anti-VEGF therapy have been 
identified. The presence of single nucleotide polymorphisms has been suggested as 
patients carrying particular SNP’s presented better overall survival, though the 
mechanisms through which the presence of specific SNP’s increases response to 
treatment are still unclear (23). The presence of VEGF isoforms has also been 
suggested as a marker of response to anti-VEGF targeted therapies. Alternative RNA 
splicing originates four VEGF isoforms with specific affinities to the extracellular 
matrix. The smaller VEGF isoform, which lacks the ability to bind to the 
extracellular matrix, circulates in the plasma and provides a more accurate indication 
of the VEGF levels produced by a tumour. Metastatic breast cancer patients with 
high levels of this isoform presented better progression free survival and overall 
survival after treatment with anti-EGFR therapies. However, no such correlation was 
observed in metastatic colorectal cancer patients (24). 
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The mutational status of KRAS is a good indicator of the outcome of anti-
EGFR therapies as patients with mutant KRAS tumours rarely respond to treatment 
with Cetuximab (25). However, anti-EGFR therapies are also only effective in 60-
70% of patients with wild type KRAS tumours (26).  In these tumours, BRAF 
mutational status, EGFR amplification and PTEN expression have been proposed as 
indicators of response to treatment with Cetuximab (25, 27). The use of targeted 
therapies is also limited by serious side effects (28).  
 Despite advances in cancer therapy, patients diagnosed with metastatic 
colorectal cancer still face a very poor prognosis. Given the now known association 
between a tumour’s individual characteristics and response to treatment, it is 
fundamental to understand the mechanisms of action of available therapies in order 
to identify patients more likely to benefit from them. There is also a pressing need 
for the development of new therapeutic options for those patients that do not respond 
or present severe side effects to the currently available ones. These new therapies 
should target the pathways involved in the initiation and progression of colorectal 
cancer so that a wider and more effective range of therapeutic solutions can be 
offered to all patients. In order to achieve these aims, a study model that better 
represents the complexity of human disease and the individual characteristics of each 






1.3– Initiation of colorectal cancer 
 In recent years, the idea that colorectal cancers arise and are 
maintained by a small number of cells with stem cell like properties such as self-
renewal and pluripotency has been suggested. Cancer stem cells are thought to derive 
from normal intestinal stem cells with deregulated functions that eventually lead to 
neoplastic transformation (29). This notion is supported by the fact that β-catenin, 
which is strongly involved in the development and progression of colorectal cancer, 
also plays a fundamental role in the regulation of the intestinal stem cell niche (30).  
The human intestinal epithelium is a rapidly proliferating tissue that self 
renews every five days. In the normal epithelium a tight balance is constantly 
maintained between proliferation, migration and differentiation in order to assure the 
tissue’s continuous renewal (31). Figure 1.1 shows a schematic representation of the 
intestinal crypt and the mechanism of proliferation and differentiation of the different 
cell types that form the intestinal epithelium, as they progress upwards in the crypt. 
In the normal intestinal epithelium there are two main compartments where 
stem cells have been shown to be located: the bottom of the intestinal crypts, and the 
+4 position immediately above the Paneth cells. The location of the stem cell 
compartment at +4 position was proposed in the 1950’s and later on demonstrated by 
Potten et al using label retention assays (32, 33). Barker et al investigated the role of 
a group of cells located at the base of the intestinal crypts known as crypt base 
columnar cells that express Lgr5 (Leucine-rich-repeat containing G-protein-coupled 














Figure 1.1: Schematic representation of the intestinal crypt.  Stem cells 
divide and start migrating upwards in the crypt towards the villus in the small 
intestine or the lumen in the colon, as they differentiate into the different types of 
cells that form the intestinal epithelium. Paneth cells in the small intestine and 
Goblet cells in the colon migrate to the bottom of the crypts where they form a 





This protein was identified as a Wnt target and is expressed in the crypts but not villi 
of mouse intestines. Using lineage tracing experiments, the group demonstrated that 
all 4 types of differentiated intestinal cells originated from these particular group of 
Lgr5 expressing cells (34). These findings were shortly after supported by 
observations that single sorted Lgr5(+) stem cells have the ability to originate crypt-
villus structures in culture (35). There is therefore strong evidence that both the cells 
located at the +4 position, and the Lgr5(+) cells located in the crypt base are stem 
cells capable of originating all intestinal epithelial lineages. However, the nature of 
the relationship between the two stem cell compartments has, until recently, been 
poorly understood. In a recent publication, Tian et al (36) demonstrated that, upon 
tissue injury, slow cycling label retaining Bmi1(+) cells located at position +4 are 
capable of  originating Lgr5(+) cells and subsequently repopulating the intestine. 
This suggests that the rapidly cycling Lgr5(+) cells are not fundamental for intestinal 
homeostasis, and that in their absence Bmi1(+) cells provide an alternative stem cell 
pool. Interestingly, this work was shortly followed by the work of Takeda et al (37) 
who demonstrated that each stem cell pool is capable of giving rise to the other 
suggesting a bidirectional lineage relationship between the two stem cell 
compartments. Though the work present by these authors provides an explanation for 
the presence of two stem cell compartments in the intestine, more work is needed to 
fully elucidate the mechanisms that regulate homeostasis between these two groups 
of stem cells.  
The concept of cancer stem cell dates from over 30 years ago and it 
originated from observations that only a small group of cancer derived human 
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myeloma cells were capable of originating colonies when cultured in soft agar (38). 
The cancer stem cell hypothesis proposes that cancer stem cells originate from 
normal stem cells with deregulated cellular functions that lead to neoplastic 
transformation. This notion is supported by the fact that features present in normal 
stem cells like the capacity to indefinitely self renew and to differentiate into various 
cell types as well as high telomerase activity are also found in cancer stem cells (29). 
It is therefore legitimate to assume that markers used for the identification of normal 
epithelial stem cells would also be present in cancer stem cells originating from the 
same tissue.  The expression of Lgr5 was therefore used by Barker et al to 
demonstrate that the proposed intestinal stem cells can also originate and maintain 
adenomas in mice upon loss of APC (39). A similar study was performed by Zhu et 
al who demonstrated that a specific group of cells located at the base of the intestinal 
crypts and co-expressing Lgr5 and Prominin1 (Prom1 or CD133) were responsible 
for the maintenance of the whole intestinal cell lineage, and were also capable of 
originating adenomas upon activation of Wnt signalling in the presence of mutant β-
catenin (40). The use of CD133 as a marker for colorectal cancer initiating cells was 
also demonstrated in mouse xenograft models (41, 42), though other authors have 
also presented evidence that CD133 expression is not restricted to intestinal stem 
cells or cancer initiating cells, and that this protein has no obvious functional role in 
tumour development (43, 44). Other markers or combination of markers such as 
EpCam, CD44, CD166, CD29, CD24, and Bmi1 have also been proposed (45-48) 
but the significance of these markers still generates some controversy.  
Though the theory that cancer stem cells are the driving force behind the 
initiation and maintenance of colorectal cancer is well established in murine models 
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of intestinal neoplasias, this has not yet been confirmed in human tumours. 
Nevertheless, colorectal cancer stem cells have recently been proposed as promising 
targets for therapeutic intervention (49). As the cancer stem cell field is rapidly 
evolving, and tools for the identification of markers become apparent it will soon be 
established if this can be applied to the human disease.  
 
Regardless of whether it occurs in stem cells or in any other cells that form 
the intestinal epithelium, colorectal cancer initiation and progression results from two 
main events: activation of oncogenes and the mutational inactivation of tumour 
suppressor genes. A total of four or five mutations in these genes are needed for the 
formation of a malignant tumour, but fewer mutations are necessary for the 
development of the benign form of the disease. Fewer or no additional mutations are 
also thought to be needed for carcinomas to progress towards metastatic disease (7, 
50, 51).  
Colorectal cancer initiating mutations can occur sporadically or due to 
inherited predisposition. Sporadic colorectal cancers account for 75-80% of cases 
(52) while 3% of tumours are found in patients with Lynch Syndrome or Hereditary 
Non Polyposis Colorectal Cancer (HNPCC) (53), and 1% occur in patients with 
Familial Adenatous Polyposis (FAP) (54). The causes leading to the development of 
the remaining 15% of colorectal cancers are still unclear (55).  FAP is caused by the 
mutation of the tumour suppressor gene Adenomatous Polyposis Coli (Apc) while 
HNPCC originates from mutations in mismatch repair genes such as MSH2, MLH1, 
PMS2 and MSH6 (56, 57).  
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Somatic Apc mutations are also present in approximately 70% of sporadic 
colorectal cancers and are considered an initiating event in the development of the 
disease (58). The APC protein is part of the complex responsible for the degradation 
of β-catenin in the cytoplasm. Some tumourigenesis models suggest that when APC 
is mutated, β-catenin is translocated to the nucleus where it activates the transcription 
of several genes involved in carcinogenesis (59). However, other reports indicate that 
APC mutations alone are not sufficient to induce nuclear accumulation of β-catenin 
(60, 61). Mutations of the β-catenin gene are also present in the early stages of 
tumourigenesis and are found in approximately 50% of sporadic colorectal tumours 
carrying wild type APC. Mutations in APC and β-catenin are mutually exclusive (31, 
62, 63).  
 
1.4 – Progression of colorectal cancer 
Colorectal cancer progression from adenomas or adenomatous polyps, into 
carcinoma, and into metastatic disease occurs through continuous accumulation of 
mutations in genes like growth factors and respective receptor genes, cell cycle 
checkpoint genes, and apoptosis related genes. These mutations follow loss of APC 
and are acquired at different stages of cancer development (56). As progressively 
more aggressive tumours continue to accumulate mutations, it is the number and not 
the sequence of these mutations that defines the tumour’s individual biological 
properties (50). These individual properties will later on define patient response to 
treatment. 
Mutations in the tumour suppressor gene p53 are one the most common 
events in the development of colorectal cancer playing a critical role in 
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carcinogenesis and tumour progression as this protein is involved in the regulation of 
cell cycle, apoptosis and DNA repair (64). Mutations in this gene have been found in 
over 40% of colorectal tumours and are associated with poor prognosis (65).  
Another common event in the development of colorectal cancers is allelic 
losses on chromosome 18 (66). This region encodes for the tumour suppressor genes 
Smad2, Smad3 and Smad4 which mediate TGF-β signalling, and therefore the 
presence of mutations in these genes is also associated with colorectal cancer 
progression (67). Figure 1.2 shows a diagram of the genes most commonly involved 
in the initiation and progression of colorectal cancer.  
Mutations in KRAS, a member of a family of proteins responsible for the 
regulation of signal transduction pathways involved in cell proliferation, 
differentiation, migration and apoptosis, are thought to follow APC mutations, 
promoting the progression from adenomas into carcinomas (68, 69), and are now 
known to be required for nuclear translocation of β-catenin together with 
homozygotic Apc mutations (70). KRAS is involved in the activation of several 
pathways, of which the best characterised is the ERK1/2 pathway, and mutations that 
lead to up-regulation of KRAS are fundamental for the maintenance and progression 
of colorectal cancers (71). A much higher frequency of KRAS mutations has been 
found in sporadic colorectal adenomas when compared to adenomas from patients 
with FAP which suggests that different molecular mechanisms are involved in the 

















Figure 1.2: Model for genetic alterations in the development of colorectal 
cancer.  Two main pathways involved in the development of colorectal cancer: 
mutations in the APC gene followed by mutations in KRAS and p53 (red 
arrows); and mutations in mismatch repair genes and microsatellite instability 
(blue arrows). Black arrows show less characterised pathways that are 




1.4.1 – The Ras/Raf/MEK/ERK pathway 
The mammalian MAP Kinase pathways which include four distinctly 
regulated groups: the extracellular signal regulated kinase 1/2 (ERK1/2), c-Jun N-
terminal kinase (JNK), p38 and ERK5 pathways, are signalling cascades that allow 
communication between the cell membrane and the nucleus. These pathways play an 
important role in controlling cellular physiology and are often deregulated in disease 
states (74, 75).  
The ERK1/2 pathway is involved in a variety of cellular processes such as 
cell cycle regulation, proliferation, survival, differentiation and apoptosis all of 
which are fundamental for normal development (76, 77). In normal cells, the ERK1/2 
pathway is activated in response to extracellular and intracellular stimuli such as 
growth factors, serum, phorbol esters, cytokines, osmotic stress and microtubule 
disorganisation (78). The ERK1/2 signalling cascade is initiated by activation of cell 
surface receptors and regulated by the binding of a Ras GTPase family member 
(Hras, Kras or Nras) to a member of the raf kinase family (C-raf, A-raf or B-raf). Raf 
family members then phosphorylate MEK1/2 which in turn activate ERK1/2 (79, 
80). A schematic representation of the pathway is shown in Figure 1.3.  
ERK1/2 has a variety of targets that range from other kinases, phosphatases 
and transcription factors which explains why this pathway is involved in such diverse 
cellular functions. Factors such as cell type and cellular localisation determine which 




















Figure 1.3: Schematic representation of the Ras/Raf/MEK/ERK pathway. 




Upon activation of the pathway, a great proportion of ERK1/2 is quickly 
translocated into the nucleus where it activates several substrates such as SRC-1, 
Pax6, NFAT, Elk-1, and MEF-2, c-fos, cjun, c-myc and STAT (78, 80). ERK1/2 
remains in the nucleus during G1 phase of the cell cycle, playing a fundamental role 
in the progression to S phase (82). However, ERK1/2 alone is not sufficient to induce 
cell cycle progression (83), and once in the nucleus activates Elk-1, Sap-1a and 
TIF1A which are also involved in the mitotic process and cell growth (84-86). 
ERK1/2 is then rapidly inactivated at the G1-S phase transition and exported from 
the nucleus (87). ERK1/2 can also promote cell survival by affecting FOXO 
transcription factors and perturbing activation of genes responsible for the induction 
of apoptosis like Bim and FasL, and genes involved in cell cycle regulation like p27 
and Cyclin D, or by destabilisation of both Bim and Bad (88). ERK1/2 is also known 
to activate cytosolic and membrane proteins PLA2, CD120a, Syk and calnexin; and 
cytoskeleton proteins like neurofilaments and paxillin (78, 80).  
Though activation of the ERK1/2 pathway is generally associated with 
proliferation and survival, there is also evidence that, depending on cell type and 
stimuli, ERK1/2 can also induce cell death. Retention in the cytoplasm seems to be 
an important factor for ERK1/2 induced apoptosis (88). Park et al have shown that 
sustained ERK1/2 activation can induce cell cycle arrest in various cell types (89), 
and reports of ERK1/2 induced apoptosis in response to DNA damage can also be 
found in the literature (90, 91).  
The Ras/Raf/MEK/ERK pathway is tightly regulated by a series of negative 
feedback mechanisms that control the magnitude and duration of the signal and 
determine which cellular functions are promoted. These mechanisms can be short 
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term ERK1/2 negative feedback phosphorylation of upstream members of the 
pathway or long term effects that require new protein synthesis. Phosphorylation of 
the Ras exchange factor SOS by ERK1/2 induces disassembly with Ras and 
termination of its activation (81, 92), Raf phosphorylation by ERK1/2 inhibits Raf’s 
ability to phosphorylate MEK1/2, and phosphorylation of Receptor Tyrosine Kinases 
(RTK) by ERK1/2 inhibits signal output upstream of Ras. Long term effects involve 
ERK1/2-dependent induction of transcription of Dual Specificity Phosphatases 
(DUSPs) which can de-phosphorylate and inactivate ERK1/2 (92, 93). 
Deregulated ERK1/2 pathway is present in about one third of all cancers (78). 
Up-regulation of the ERK1/2 pathway results from constitutive activation of cell 
surface receptors or gain of function mutations in ras or raf family members (94, 95) 
leading to amplification of signals involved in a variety of cellular functions that 
sustain tumour proliferation and survival (96). Mutations in the ras gene are present 
in approximately 30% of all cancers (68) and the frequency of mutations of each ras 
family member varies with cancer type (97). In colorectal cancer, the most frequently 
mutated member of the ras family is KRAS with a frequency of over 40% (98, 99). 
BRAF mutations occur in 12% of colorectal cancers (98). As KRAS and BRAF 
mutations are mutually exclusive their combined frequency amounts to over 50% of 
all colorectal cancers (100).  
There is substantial evidence that KRAS and BRAF mutations contribute to 
the maintenance and progression of colorectal cancers. Disruption of the single 
mutant KRAS allele induced loss of tumourigenic ability of colorectal cancer cell 
lines implanted in immnuno-compromised mice (101, 102). Recent reports also show 
that mutant KRAS and its effector RAF1 are necessary for tumour invasion and 
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formation of metastasis (103). Matos et al have shown that mutant BRAF 
functionally cooperates with Rac1b to sustain colorectal cancer cell viability, 
providing an alternative survival pathway in cells carrying wild type KRAS (104).  
The presence of KRAS and BRAF mutations has been associated with poor 
prognosis and resistance to treatment with anti-EGFR therapies in colorectal cancer 
patients (105, 106). Targeting the pathway downstream of these mutations is 
therefore a promising therapeutic option. 
 
1.5 – MEK1/2 inhibitors 
 To date, several MEK1/2 inhibitors have been developed but only a few have 
reached clinical evaluation. The first MEK1/2 inhibitor to be developed was 
PD98059 which inhibited both inactive forms of MEK1 and MEK2 but failed to act 
on the phosphorylated form of the proteins (107). Two other MEK1/2 inhibitors were 
identified, U0126 and Ro 09-2210, but due to their pharmaceutical limitations none 
of these compounds were even taken into clinical evaluation. Nevertheless, PD98059 
and U0126 provided useful tools for the study of ERK1/2 pathway functions in 
normal and malignant cells (108).  
 Pfizer’s CI-1040 was the first MEK1/2 inhibitor to enter clinical trials. This 
compound is a potent non-ATP and non-ERK1/2 competitive MEK1/2 inhibitor that 
was shown to inhibit the growth of colon tumours by a maximum of 80% in mouse 
and human xenografts models (109). However, the use of this compound in the clinic 
was limited by insufficient anti-tumour activity, poor solubility and low bio-
availability (108).  
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 Pfizer’s second generation MEK1/2 inhibitor PD0325901 has a similar 
structure to CI-1040 but enhanced pharmaceutical properties. However, in clinical 
trials this compound presented severe side effects and it’s development was 
discontinued (108). 
 GDC-0973 (XL518) has shown strong growth inhibition effects in cell lines 
harbouring KRAS and BRAF mutations. In vivo studies have shown that a single dose 
of this agent is enough to inhibit ERK1/2 phosphorylation for a period of 48h. 
Clinical studies show that this agent is well tolerated and Phase I clinical trials are 
ongoing (108, 110). 
 RDEA119 (BAY869766) is a potent allosteric MEK1/2 inhibitor that 
efficiently inhibits growth in cell lines, and exhibits potent activity in xenograft 
models of melanoma, colon and epidermal carcinoma. RDEA119 is currently in 
Phase I trials as a single agent and in combination with Raf inhibitor Sorafenib (108, 
111). 
 
1.5.1 – AZD6244 (ARRY142886 / Selumetinib) 
 One agent that I am especially interested in is the MEK1/2 inhibitor 
AZD6244 (ARRY142886 / Selumetinib). In particular, I wish to investigate the 
response to treatment with this agent using human colorectal tumour explants, and 
identify markers of sensitivity / resistance that will allow for the selection of those 
patients more likely to benefit from treatment with AZD6244.  
 The MEK1/2 inhibitor AZD6244 developed by AstraZeneca is a highly 
selective non allosteric and non ATP competitive compound with nanomolar activity 
against purified MEK1/2 enzyme (112, 113). The molecular structure of AZD6244 is 
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shown in Figure 1.4. This agent strongly inhibits ERK1/2 phosphorylation shortly 
after exposure in cell lines and xenograft models (94, 114) and in lymphocytes from 
12-O-tetradecanoylphorbol-13-acetate-treated whole blood used as a surrogate for 
tumour tissue in clinical trials (115). AZD6244 induces cell cycle arrest at G1 phase 
in cell lines, evidenced by a decrease in Cyclin D1 and CDK4 expression, and an 
increase of cell cycle inhibitors p21 and p27 (95). However, sensitivity to this agent 
is variable and induction of apoptosis is rarely reported. The mutational status of 
KRAS and BRAF has been proposed as an indicator of sensitivity to AZD6244. 
However, different authors report opposite observations. While Davies et al (94) 
report that cells carrying these mutations are more sensitive to the drug, Balmanno et 
al (114) have demonstrated that mutational status of KRAS or BRAF cannot be used 
as an indicator of sensitivity to AZD6244 in colon cancer cell lines. 
 AZD6244 has completed Phase I and II clinical trials with no severe side 
effects being associated with its intake, but disease stabilisation is generally reported 
as the best outcome (115-118).  
AZD6244 has also shown promise when used in combination with other 
agents such as Akt, PI3K or mTOR inhibitors (119-121). Therefore, I wish to test the 
potential of therapeutic combinations of AZD6244 and aspirin, as several reports 
indicate that the pathways targeted by these drugs have some common substrates 




































Figure 1.4: Schematic representation of AZD6244 chemical structure. 
Chemical structure of 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-
3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide .Adapted from 
Wang et al (112). 
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1.6 – Aspirin 
 Aspirin or acetylsalicylic acid is a Non Steroidal Anti Inflammatory (NSAID) 
drug commonly used to relieve mild pain, fever and inflammation. Regular aspirin 
intake is long known to prevent cardiovascular disease (122, 123) and this agent is 
routinely prescribed to patients for the treatment and prevention of this condition. 
Recent reports have also shown evidence that regular aspirin intake reduces the risk 
of colorectal cancer (124, 125). However, aspirin intake is associated with serious 
gastrointestinal and renal side effects (126).  
 Despite extensive research, the mechanisms of action of this drug are still 
elusive, but aspirin seems to affect a variety of cellular functions. Aspirin is a known 
COX inhibitor but reports show that it can also induce COX-2 expression in the 
gastrointestinal tract (127, 128). COX enzymes 1 and 2 are almost identical in 
structure but have evolved distinct functions. COX-1 is involved in the synthesis of 
protective prostaglandins that preserve integrity of intestinal lining and normal renal 
function, while COX-2 is involved in the inflammatory response and cell growth 
control (129). 
 The NF-κB pathway regulates the transcription of many genes involved in the 
immune and inflammatory response (130), and is thought to promote cell 
proliferation and inhibit apoptosis (131). It has been hypothesised that the activation 
of this pathway contributes to the initiation and progression of cancer by inducing 
cellular transformation and proliferation, preventing elimination of pre-neoplastic 
and malignant cells, and up-regulating anti-apoptotic signals. NF-κB pathway is also 
thought to promote angiogenesis and the development of metastasis (132). The host 
lab has identified a novel mechanism for switching off NFκB activity in colorectal 
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cancer cells. In this model, aspirin activates the NF-κB pathway through degradation 
of IκB which results in nuclear translocation of NF-κB and nucleolar sequestration of 
RelA leading to reduced transcription of anti-apoptotic signals (133, 134). Treatment 
with aspirin also induces Cyclin D1 degradation and cell cycle arrest in colorectal 
cancer cell lines (135). 
Recent evidence also shows that aspirin inhibits mTOR, activates AMPK, 
and induces autophagy in colorectal cancer cells (136). The mammalian target of 
rapamycin, mTOR, plays a fundamental role in various signalling pathways 
deregulated in cancer (137) while AMPK, a cellular energy sensor, responds to 
cellular stress by suppressing cellular growth through inhibition of the mTOR 
pathway (138).  
 Though evidence shows that aspirin is a potent anti-cancer agent, its use is 
limited by the presence of side effects. It is therefore essential to unravel the exact 
mechanisms through which aspirin acts on cancer cells so that other drugs that mimic 
these mechanisms but with reduced side effects can be developed.  
In order to study these mechanism as well as the mechanisms of response to 
MEK1/2 inhibitor AZD6244, and the potential for combination therapy with aspirin, 
a model of human colorectal cancer that is more relevant to the clinic should be used.  
 
1.7 – Models of Colorectal Cancer 
Several models of colorectal cancer have been developed, but so far, very few 
have been able to recapitulate the tumour’s in vivo environment and original 
characteristics, and therefore accurately represent the variability of human disease. 
Ideally, study models should be able to reproducibly mimic the cell-cell and cell-
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stroma interactions, reflect the invasive behaviour of tumour cells in vivo, and enable 
the study of the different mechanisms of tumour biology (139). However, replicating 
the immune component of colorectal cancers still presents a considerable challenge 
even in models capable of meeting the above criteria.  
 
1.7.1 – Cell line models 
Cell line models, which have been obtained from primary culture of isolated 
human colonic tumour cells or from immortalised normal epithelial cells, provide 
useful and widely used tools to unravel signalling pathways involved in colorectal 
cancer and to quickly obtain drug response results. However, these models are often 
two-dimensional (2D) systems that do not accurately mimic the structure, function 
and physiology of the original tissue (140). Even in three-dimensional (3D) systems, 
where the original tissue architecture is thought to be maintained, the distribution of 
oxygen, nutrients, and signalling molecules; and cell-cell and cell-matrix 
interactions, are not representative of the tissue’s in vivo environment (141). Cell 
culture models are also limited by the genotypic and phenotypic changes that result 
from the immortalisation process and continuous passages, which makes them less 
representative of the tissue of origin (142).  
 
1.7.2 – Murine models 
 Murine models of colorectal cancer have been invaluable tools for studying 
the events involved in the initiation and progression of this disease. The most widely 







mice are heterozygous for the Apc gene, carrying one mutated and one 
functional copy of this tumour suppressor gene. While mice carrying homozygous 
Apc mutations die during embryonic stage, mice with heterozygous mutations 
develop multiple intestinal tumours within weeks of birth providing a study model of 
the early stages of carcinogenesis (143). Though loss of APC is considered an 
initiating event in the development of colorectal cancer, mutations in other genes are 
needed for tumours to progress towards malignant disease. Modifications of the Min 
mouse obtained by interbreeding with mice carrying mutations in other genes like 
KRAS, p53 or members of the Wnt pathway have also been developed to study the 
mechanisms underlying tumour progression (144). 
Even though Apc
min/+ 
mice are an important tool for studying the events 
involved in the initiation of colorectal cancer, the model has limitations. Apc
min/+ 
mice develop polyps mainly in the small intestine while in humans polyps appear 
mainly in the colon. Apc
min/+ 
mice rarely present invasive adenocarcinomas, and the 
presence of metastasis has never been reported, making them inadequate for the 
study of later stages of the disease (145). Even modifications to the Apc
min/+
 mouse 
which can display more aggressive tumours are limited by differences in phenotype 
between mice and human disease. Also, Apc
min/+ 
mice predisposition to colorectal 
cancer is strain dependent and regulated by a genetic loci designated as Modifiers of 
Min or Mom. To date a variety of Mom loci have been identified. Based on this, 
Apc
min/+ 
mouse strain and breeding programmes need to be carefully chosen for each 




Other genetically engineered mouse models have been developed in which 
mutations in genes involved in the initiation and progression of colorectal cancer are 
introduced. However, manipulation of these genes in mice does not completely 
recreate the phenotype observed in the human disease, and it may not represent the 
mechanisms behind sporadic colorectal cancer. Also, in such models, genetic 
manipulation is mostly based on loss of function while in human cancers many 
mutations lead to gain of function (148). Genetically engineered mice also display 
considerable variability in terms of tumour development regarding frequency, growth 
rate and tumour location caused by modifier alleles characteristic of each individual, 
that can significantly influence tumour initiation or response to therapeutic agents 
(149).  
Transplantation or xenograft models are a common tool for studying 
metastatic colorectal cancer, and therapeutic responses. In this model, human cancer 
cell lines or fragments of human tumours are transplanted into immuno-
compromised mice where they form tumours if cells are used, or continue to develop 
in the case of tumour fragments, become invasive and eventually form metastasis 
(150). However, the formation of metastasis is a lengthy process that occurs only in a 
small number of animals. Xenografts are also often not representative of the genetic 
and histological characteristics of the human tumours, and thus not entirely 
predictive of therapeutic response (149). In addition, the use of immuno-
compromised mice does not allow for assessment of the role of the immune 
component in tumourigenesis (151). Hence, humanised mice have recently become a 
popular solution to overcome this limitation. Mice humanisation techniques include 
ablation of the mouse immune system followed by engraftment of human immune 
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cells (152), transgenic expression of human immunoreceptor genes (153), or the use 
of recombinase mediated genomic replacement through which human loci for the 
entire T-cell and B-cell receptors or even major specific compatibility complexes 
might be knocked in in the mice. However, these techniques also present technical 
and data interpretation limitations as any modifications introduced in the models 
must be taken into account when analysing the data (151).  
 
Inflammation-mediated mouse models have been used to show that chronic 
inflammation can develop into colorectal cancer. In these studies, mice were given a 
single dose of Azoxymethane (AOM) followed by prolonged treatment with dextran 
sulphate sodium (DSS) which resulted in chronic colitis, high-grade dysplasia and 
consequent progression to colorectal cancer. However, multiple treatments with 
carcinogens during long experimental periods are necessary to induce large tumours. 
Also, these mice develop invasive colonic carcinomas with ras mutations but rarely 
present Apc or p53 mutations (154), and therefore lack fundamental characteristics of 
the human disease. 
Other murine models have been developed to study different aspects of 
colorectal cancer like carcinogen induced models to study sporadic colorectal cancer; 
Tgfb1 mutant mice to study later stages of the disease; or mismatch repair (MMR)-
deficient models to study Hereditary Non Polyposis Colorectal Cancer (147, 155). 
Despite being fundamental tools to study different aspects of colorectal cancer, 
murine models are often driven by specific mutations and therefore present 
characteristic aetiology that is distinct from the human colorectal cancers. These 
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models also do not take into account the phenotypic differences between mice and 
human disease, which limits direct extrapolation from one to the other. 
 
1.7.3 – Multicellular tumour spheroid models 
Multicellular tumour spheroids are 3D aggregates of tumour cells or of a 
mixture of tumour and stromal cells that can be obtained from a broad range of 
human tumour cell lines or from tissue previously subjected to disaggregation 
techniques, with the former being more common. This model, initially used to study 
tumour radiobiology is still mostly applied in therapeutic response studies, though 
some investigators have also used it to study basic biological mechanisms (156, 157). 
Being 3D structures, multicellular tumour spheroids can recreate the complex 
mechanisms of continuous cell-cell and cell-matrix interactions present in living 
tissues, and can also present various pathophysiological features of avascular 
tumours and developing metastasis (139, 158). 
There are several methods of obtaining multicellular tumour spheroids but the 
main requirement of this technique is that the cells, either cell lines or cells 
disaggregated from tissues ex vivo, attach to each other or to an artificial matrix in 
order to form the 3D structure. The spinner flask method, with which cells are grown 
as a suspension culture in liquid medium with constant agitation to impede the 
adhesion of the cells to the flask wall and instead promote the adhesion between 
cells, is the most common method. Other alternatives are: liquid overlay cultures, 
microcarrier beads coated with cell binding materials (139), scaffold based cultures 
(159), or NASA’s rotary cell culture system (160).  
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Despite their general use and numerous advantages, multicellular tumour 
spheroids do not fully mimic the in vivo environment of the original tissue, especially 
when cell line derived spheroids are used. In these models, it is impossible to 
accurately say that the behaviour of the cells in terms of growth and death will be the 
same as the tumour in vivo; firstly, because tumour cell lines are often manipulated to 
suit laboratory and commercial needs, and when kept in culture can accumulate 
mutations that confer altered characteristics. Secondly, because when using cell lines 
there isn’t an original tumour to which the spheroid architecture can be compared to. 
Even spheroids obtained from disaggregated tumours might not be representative of 
the properties found in the original tissue due to the requirement of an extracellular 
matrix that, depending on its nature, can alter the cells behaviour in culture (159). 
Regardless, of such limitations human multicellular tumour spheroids obtained from 
disaggregated tissue are becoming increasingly more popular and their use in a 
variety of application has been reported by several authors (41, 48, 161, 162).  
The culture of multicellular spheroids of normal intestinal tissue has also 
been reported by several authors (35, 163, 164). In a recent publication, Sato et al 
(163) described a method for the long term culture of organoids derived from human 
intestinal tissue obtained from surgery. The authors reported how, by adding 
nicotinamide, a member of the vitamin B family; A83-01, an Alk3/4/5 inhibitor; and 
SB202190, a p38 inhibitor to the culturing media they were able to maintain the 
organoids in culture for periods of more than 6 months. However, the authors also 
observed a lack of cell differentiation shown to be caused by the presence of 
nicotinamide and SB202190. The same authors also reported that the use of R-
sponding1, a Lgr5 ligand essential for activation of the Wnt signal in the intestinal 
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crypt (165); and noggin, a protein involved in intestinal crypt formation and polyp 
growth (166) are fundamental for the long term maintenance of mouse intestinal 
adenoma organoid cultures. These culturing systems can, therefore, be used to study 
basic aspects of intestinal stem cell biology and cell differentiation, and to investigate 
response to therapeutic agents to be used in a variety of intestinal conditions.  
 
1.7.4 – Ex vivo models 
 Ex vivo models are three dimensional culture systems of tissue explants that 
fill the gap between the 2 dimensional cell culture models and the use of animal 
models. Because they more accurately represent the 3D architecture found in the in 
vivo environment preserving cell-cell and cell-stroma interactions, they are valuable 
tools for studying other aspects of intestinal biology such as morphology and 
epithelial homeostasis, cell differentiation, organisation and biochemical responses. 
They are more appropriate tools for the development of new therapies, and for 
testing the efficacy of currently available or new therapeutic agents in a clinically 
relevant context.  
There are three main requirements to successfully culture human tissue ex 
vivo: the presence of an extracellular matrix; the presence of interstitial fluid rich in 
nutrients and signalling molecules required for tissue homeostasis; and the 
arrangement of the cells in culture must be such as to enable appropriate cell-cell and 
cell-matrix interactions, and the exchange of biological effectors (139). Several 
methods for long term culture of tumour explants that include different approaches to 
these requirements have been described in the literature over the last 50 years. These 
methods allow for the maintenance of tissue architecture, homeostasis and oncogenic 
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properties, and can be used for a variety of applications including drug response 
assays (167-169). However, the culture of human tumour explants ex vivo is not 
widely and routinely used. Availability of fresh tissue samples can be a limiting 
factor, along with the ethical restrictions imposed to the use of human biopsies, and 
the need for patient consent. 
 
1.8 – Project Aims 
 The aims of this project were: 
I. To develop a method of culturing human colorectal tumour explants ex vivo 
that allows for the maintenance of the tumours individual characteristics 
providing a robust and representative model of human colorectal cancer. 
II. Use this model to test the pharmacodynamic and phenotypic effects of the 
MEK1/2 inhibitor AZD6244. 
III. Investigate the relationship between pharmacodynamic and phenotypic 
responses and known genetic factors of sensitivity / resistance to AZD6244. 
IV. Use this platform to explore the potential for combination therapy with 


























2.1 - Materials and reagents 
2.2.1 – Tumour explant culture 
 Waymouth medium (Gibco) supplemented with foetal calf serum (10%, Gibco), 
penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, Gibco), ascorbic acid 
(300μg/mL, Sigma), FeSO4.7H20 (0.45μg/mL, Merck), antimycotic/antibiotic mix 
(1:100, Sigma), and hydrocortisone (3μg/mL, manufactured by Biochrom AG, 
supplied by Autogen Bioclear).  
 
 MEM medium (Sigma) supplemented with foetal calf serum (10%, Gibco), 
penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, Gibco), 
antimycotic/antibiotic mix (1:100, Sigma), and L-glutamine (4mM, Sigma). 
 
 StemPro hESC SFM stem cell medium (Gibco): DMEM/F-12 + 1x Glutamax 
media supplemented with 1x StemPro hESC SFM Growth supplement, 1.8% BSA, 
8ng/mL FGF-basic, 0.1mM 2-Mercaptoethanol, penicillin/streptavidin (1.7g/mL 
and 1.3g/mL respectively, Gibco), and antimycotic/antibiotic mix (1:100, Sigma). 
 
 FGF-basic (Invitrogen) reconstituted in 10mM Tris (pH 7.6). 
 
 Collagen gels supplied by First Link Ltd and prepared according to 
manufacturer’s instructions: 4.5mL of collagen gel were mixed with 0.5mL of 
supplemented MEM media, and pH was adjusted with 1M NaOH until solution 
turned from yellow to pink in colour. Gels were then plated on 24-well plates 
(0.5mL of gel solution per well) and allowed to set for 5min at 37ºC. 
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2.1.2 – Cell culture 
 RPMI 1640 media (Gibco) supplemented with foetal calf serum (10%, Gibco), 
penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, Gibco), 
antimycotic/antibiotic mix (1:100, Sigma) was used to culture HRT18 cells. 
 
 McCoy’s media (Gibco) supplemented with foetal calf serum (10%, Gibco), 
penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, Gibco), 
antimycotic/antibiotic mix (1:100, Sigma) was used to culture RKO and HCT116 
cells. 
 
2.1.3 – AZD6244 and Aspirin treatments 
 AZD6244 (AstraZeneca.) AZD6244 was dissolved to 10mM stock solution in 
DMSO. Working solutions were also dissolved in DMSO. Stock and work 
solutions were stored at 4ºC. 
 Aspirin was obtained as acetyl salicylic acid from Sigma, and 500mM stock 
solutions were prepared in house by slowly adding 5M NaOH to an acetyl salicylic 
acid solution previously prepared with water. This solution was allowed to 
hydrolyse overnight and pH was adjusted to 7. Stock solution was stored at -20ºC 







2.1.4 – Viability assays 
2.1.4.1 – MTT based in vitro toxicology assay 
MTT assay used to assess viability of tumours and outgrowths while in 
culture was supplied by Sigma and used according to manufacturer’s instructions. 
MTT reagent was reconstituted in 3mL of sterile PBS, aliquoted and frozen until use.  
  
2.1.4.2 – Sulforhodamine B colorimetric cytotoxicity assay 
 Sulforhodamine B (SRB) was used to measure the effects of treatment with 
AZD6244 and aspirin, individually and in combination, in colorectal cancer cell 
lines. 
 
 25% Trichloroacetic acid solution:  trichloroacetic acid (Sigma) was dissolved in 
water to a concentration of 25% and stored at 4ºC. 
 
 1% acetic acid: acetic acid (Sigma) was diluted to a concentration of 1% with 
water immediately before use. 
 
 0.4% SRB in 1% acetic acid: sulforhodamine B was dissolved in 1% acetic acid 
to a concentration of 0.4% and stored at 4ºC. 
 
 10mM Tris pH10.5: Tris base (Sigma) was dissolved in water to a concentration 




2.1.5 – Immunoperoxidase assay 
 TEG Buffer: 2.422g Tris and 0.38g EGTA dissolved in 2L of distilled water, and 
pH adjusted to 9. 
 
 Wash Solution 1 - 1% BSA (Sigma) + 0.2% Gelatine (Sigma) + 0.05% Saponin 
(Sigma): 2g of gelatine were added to 200mL PBS and heated in the microwave 
until dissolved. Gelatine was then added to 10g BSA and 0.5g saponin previously 
dissolved in PBS. 1L of this solution was prepared. 
 
 Wash Solution 2 – 0.1% BSA (Sigma) + 0.2% Gelatine (Sigma) + 0.05% 
Saponin (Sigma): 4g of gelatine were added to 400mL PBS and heated in the 
microwave until dissolved. Gelatine was then added to 2g BSA and 1g saponin 
previously dissolved in PBS. 2L of this solution were prepared.  
 
2.2 – Methods 
2.2.1 – Tumour explant culture 
Tumours were collected at the time of resection and immediately transferred 
to the lab immersed in culturing media. Tumours were placed in Falcon tubes 
containing sterile Phosphate Buffered Saline (PBS), washed twice by inverting the 
tubes, and then placed in Petri dishes containing sterile culturing media where they 
were dissected into 1-2mm
2 
fragments. Tumour fragments were washed once more in 
new Petri dishes containing fresh media and cultured using the methods described 
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below. Prior to placing in culture, a proportion of the tumours was routinely frozen 
and a proportion fixed as a T0 control. 
 
2.2.1.1 – Growth on stainless steel mesh 
Tumour fragments were inserted in cuts made on the edges of the stainless 
steel mesh, and these were balanced on the centre well of a culturing dish containing 
3mL of Waymouth media (Gibco) supplemented with foetal calf serum (10%, 
Gibco), penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, Gibco), ascorbic 
acid (300μg/mL, Sigma), FeSO4.7H20 (0.45μg/mL, Merck), antimycotic/antibiotic 
mix (1:100, Sigma), and hydrocortisone (3μg/mL, manufactured by Biochrom AG, 
supplied by Autogen Bioclear). Cultures were then placed in a Molecular Incubator 
Chamber (billups-rothenberg Inc.) pressurised for 3min with 95% O2 and 5% CO2, 
and incubated at 37°C with gentle rocking. Tumours explants were transferred to 
new culture dishes containing fresh media, daily. Tumours were harvested after 4 
days in culture, and frozen or fixed in 4% Formaldehyde/PBS. 
 
2.2.1.2 – Unattached growth 
Tumour fragments were immersed in 3mL of supplemented Waymouth 
media in the centre well of the culturing dish. One fragment per dish was set up. 
Tumours were cultured in a molecular incubator chamber pressurised for 3min with 
95% O2 and 5% CO2, and incubated at 37°C with gentle rocking. Daily media and 
dish changes were performed. Samples were harvested at T0, 1, 5, 10, 16, and 20 
days, frozen or fixed in 4% formaldehyde.  
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2.2.1.3 – Growth on filter paper 
Tumour fragments were individually placed on filter paper disks previously 
soaked in supplemented Waymouth media, and transferred to the centre well of a 
culturing dish containing 3mL of fresh media. Media and culture dishes were 
replaced daily. Explants were cultured in a molecular incubator chamber pressurised 
for 3min  95% O2 and 5% CO2, and incubated at 37°C with gentle rocking, and 
harvested at T0, 1, 5, 10, and 16 days,. Samples were frozen or fixed in 4% 
formaldehyde. 
 
2.2.1.4 – Growth on collagen gels 
Tumours previously washed and dissected into 1-2mm
2
 fragments were 
washed a third time in fresh  MEM media (Sigma) supplemented with foetal calf 
serum (10%, Gibco), penicillin/streptavidin (1.7g/mL and 1.3g/mL respectively, 
Gibco), antimycotic/antibiotic mix (1:100, Sigma), and L-glutamine (4mM, Sigma) 
before plating on Type I collagen gels (First Link Ltd) previously prepared according 
to manufacturer’s instructions and allowed to set in 24-well plates. Samples were 
covered with 200µL of supplemented media and incubated at 37°C with 5% CO2. 
Fresh media was added to the cultures every 2 days. Samples were harvested at T0, 
24/48h, 5, 7, 12, 16 and 28 days. Main tumour bodies were immediately frozen or 
fixed in 4% formaldehyde.  Cell outgrowths were digested with Collagenase IV as 
described below. Cultures were imaged, immediately before harvest, using a Nikon 
AZ100 macroscope with 1x magnification objective to monitor the progress of the 




2.2.1.4.1 - Digestion with collagenase IV 
Collagenase IV enzyme (200U/mL, Sigma) was solubilised in supplemented 
MEM media and filtered with a 40μm syringe filter before use. Collagen gels, 
outgrown cells and media were removed from the culture wells and placed in Falcon 
tubes to which the collagenase solution was added. This mixture was incubated at 
37°C for 45min then centrifuged at 500g for 10min at 4°C. Cell pellets were washed 
with cold PBS solution by centrifugation at 1000g for 5min at 4°C. PBS was 
discarded and pellets were immediately stored at -80°C. 
 
2.2.1.5 – Preparation of multicellular tumour spheroids 
 Tumours collected at the time of resection were immediately transferred to 
the lab immersed in culturing media. Once in the lab, tumours were washed twice in 
sterile PBS, placed in Petri dishes containing fresh PBS and dissected into 1mm
2
 
fragments. Tumour fragments and PBS were transferred to Falcon tubes, washed by 
inverting the tubes, and centrifuged at 1000rpm for 5min at 4ºC. Tumours were 
washed 3x following this procedure, and re-suspended in supplemented MEM media 
containing 1.6mg/mL Collagenase IV (Sigma). Fragments were mechanically 
disrupted by pipetting up and down with a 5mL pipette, then transferred to 
Erlenmeyer flasks (Fisher Scientific) and incubated at 37ºC for 2h with vigorous 
rocking. Digested tumours were transferred to falcon tubes and centrifuged at 
1000rpm for 5min at 4ºC. Pellets were re-suspended in PBS, washed by inverting the 
tubes, and filtered through a 500μm stainless steel mesh. Filtrate was again passed 
through a 40μm cell strainer. This filtrate was discarded and tumour fragments that 
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remained in the strainer were collected onto a Falcon tube and centrifuged at 
1000rpm for 5min at 4ºC. Pellets were re-suspended in StemPro hESC SFM stem 
cell media (Gibco) which is composed of DMEM/F-12 + 1x Glutamax media 
supplemented with 1x StemPro hESC SFM Growth supplement, 1.8% BSA, 8ng/mL 
FGF-basic, 0.1mM 2-Mercaptoethanol, penicillin/streptavidin (1.7g/mL and 1.3g/mL 
respectively, Gibco), and antimycotic/antibiotic mix (1:100, Sigma). Tumour 
fragment suspension was transferred to 6-well plates and incubated at 37ºC with 5% 
CO2. Formation of multicellular tumour spheroids was monitored daily by imaging 
with a Zeiss LSM510 confocal microscope. 
 
2.2.2 – Treatment of colorectal tumour explants 
 All colorectal tumour explant culture treatments were performed with 
culturing media supplemented with 10% foetal calf serum, as described below. 
 
2.2.2.1 – Long term treatment 
Tumour fragments were placed on collagen gels and covered with 200µL of 
supplemented MEM media containing 0, 1, 3, 5 and 10mM aspirin and cultured for 
24h or 3-6 days or 0, 1, 3, 5 and 10μM oxaliplatin (Sigma), and cultured for 24 and 
48h without media or drug replenishment. 
 
2.2.2.2 – Acute (short time point) treatment 
 Colorectal tumours collected at the time of resection were immediately 
transferred to the lab immersed in culturing media. Tumours were placed in Falcon 
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tubes containing sterile PBS, washed twice by inverting the tubes, and then placed in 
Petri dishes containing sterile culturing media and dissected into 1-2mm
2 
fragments. 
Tumours were transferred to new Petri dishes and washed with fresh media before 
plating. Treatment of tumour explants was performed in 96-well plates and in the 
presence of 10% foetal calf serum as described below: 
 
AZD6244 treatments: tumours were individually immersed in 200µL of 
supplemented MEM media containing 0, 0.1 or 3µM AZD6244, and routinely 
incubated for 1h at 37ºC with 5% CO2. The first 3 tumours treated were incubated for 
1, 3 and 6h as part of an experiment aiming to determine the minimum time point at 
which the effects of AZD6244 could be measured. DMSO concentration was 0.03% 
in all wells, including non treated controls (0μM). 
 
Treatment with combinations of AZD6244 and Aspirin: tumours were 
individually immersed in 200μL of supplemented MEM media containing: 
 0μM AZD6244 + 0.03% DMSO 
 0.1μM AZD6244 (final DMSO concentration 0.03%) 
 3μM AZD6244 (final DMSO concentration 0.03%) 
 0.1μM AZD6244 + 100μM aspirin (final DMSO concentration 0.03%) 
 3μM AZD6244 + 100μM aspirin (final DMSO concentration 0.03%) 
 0μM aspirin 
 100μM aspirin 




2.2.3 – Cell culture 
 Colorectal cancer cell lines RKO, HRT18 and HCT116 (American type 
culture collection) were selected for these assays based on their reported sensitivity 
to AZD6244 and mutational status of KRAS and BRAF. RKO cells are BRAF mutant 
while HRT18 and HCT116 are KRAS mutant.  
All cell lines were grown in T75 flasks and split every 3 days into new flasks 
with fresh media. HRT18 cells were maintained in RPMI 1640 media (Gibco) 
supplemented with foetal calf serum (10%, Gibco), penicillin/streptavidin (1.7g/mL 
and 1.3g/mL respectively, Gibco), antimycotic/antibiotic mix (1:100, Sigma). RKO 
and HCT116 cells were maintained in McCoy’s media (Gibco) supplemented with 
foetal calf serum (10%, Gibco), penicillin/streptavidin (1.7g/mL and 1.3g/mL 
respectively, Gibco), antimycotic/antibiotic mix (1:100, Sigma). 
 
2.2.3.1 – Treatment with AZD6244 
 RKO, HRT18 and HCT116 were split into T25 flasks or 6-well plates 
containing glass cover slips, and allowed to grow in supplemented culturing media 
(see materials and reagents) for 24h before treatment to assure complete adhesion 
and ~60% cell confluence. Culturing media was then replaced with fresh media 
containing 0, 0.1 or 3μM AZD6244. Cells were incubated for 1, 3 and 6h at 37ºC 
with 5% CO2. Cells grown on T25 flasks were washed with PBS and transferred to 
15mL Falcon tubes and centrifuged. Cell pellets were frozen for protein extraction 
(see section 2.2.4.4). Cells grown on cover slips in 6-well plates were washed with 
PBS and fixed in Methanol / Acetone (1:1) solution for a minimum of 30min. at 4ºC, 
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and immunocytochemical analysis for relevant markers was performed (see section 
2.2.4.3). 
 
2.2.3.2 – Treatment with combinations of AZD6244 and Aspirin 
 Prior to treatment with drug combinations growth curves for each cell line 
were established to determine the optimal plating density and time point at which 
cells achieved exponential growth. Half maximum effective concentrations (EC50) for 
each drug and cell line were also determined 
 
2.2.3.2.1 – Establishment of growth curves 
 Cells were split and plated in seven 96-well plates at increasing cell densities 
and allowed to grow for 7 days. Six replicates were set up per original plating density 
and assays were performed in triplicate for each cell line. Cells were harvested every 
day (one 96-well plate per day) and fixed. Cell viability was assessed using a 
Sulforhodamine B assay (see section 2.2.4.5.2). Growth curves were generated from 
the absorbance values.  
 
2.2.3.2.2 – EC50 calculation 
 Cells were plated at densities previously established using the growth curves 
and allowed to grow for 1 (HRT18 and HCT116 cells) or 2 days (RKO cells) until 
exponential growth was achieved. Culturing media was then replaced by fresh media 
containing increasing concentrations of AZD6244 or aspirin. Six replicates were 
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used for each drug concentration. Cells were treated for 72h (no replenishment of 
drug or media), fixed and assessed for viability using a Sulforhodamine B assay. 
Absorbance values generated from this assay were used to calculate EC50 values 
using Prism software. Assays were performed in experimental triplicates for each 
drug and cell line. 
 
2.2.3.2.3 – Drug combination assays 
 Cells were plated in 96-well plates at densities previously established and 
allowed to grow for 1 day (HRT18 and HCT116 cells) or 2 days (RKO cells) until 
exponential growth was achieved. Culturing media was then replaced by fresh media 
containing increasing concentrations of AZD6244 and aspirin. Drug concentrations 
were established based on the EC50 values previously determined for each drug. Four 
dilutions below and 3 dilutions above the EC50 values were used for each drug, and 
the range of concentrations used varied with cell line. RKO cells were treated with 
AZD6244 concentrations ranging from 0-70μM and aspirin concentrations ranging 
from 0-15mM. HRT18 cells were treated with AZD6244 concentrations ranging 
from 0-135μM and aspirin concentrations ranging from 0-25mM. HCT116 cells were 
treated with AZD6244 concentrations ranging from 0-38μM and aspirin 
concentrations ranging from 0-27mM. Six replicates of each treatment were set up 
per plate and assays were performed in triplicate for each cell line. 
 Cells were treated for 72h without replenishment of media or drugs. Cell 
viability was assessed using a Sulforhodamine B assay. Absorbance values obtained 
with this assay were then used to calculate the percentage of cell death as a result of 
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treatment with each drug individually or in combination. The effects of the drug 
combinations were determined using Compusyn software. 
  
2.2.4 – Assays 
2.2.4.1 – Fixation, Embedding and Staining of tumour samples 
 Samples were fixed in 4% formaldehyde/PBS for 24h then immersed in 75% 
ethanol for 24h, and paraffin embedded using a Sakura Tissue-Tek VIP 5 Jr machine. 
4μm tissue sections were cut using a Reichert-Jung Biocut 2030 and placed on 
Superfrost Plus slides (Thermo Scientific) for histological and immunohistochemical 
analysis. 
 
2.2.4.1.1 - Haematoxylin & Eosin staining 
 Formaldehyde fixed and paraffin embedded (FPPE) tissue sections were de-
waxed in xylene and re-hydrated by serial washes in decreasing concentrations of 
ethanol, and finally in water. Slides were immersed in haematoxylin for nuclear 
staining, differentiated in acid alcohol (1% HCl in 70% alcohol), immersed in 
lithium carbonate to remove excess dye and then in eosin for cytoplasm 
differentiation. Slides were then dehydrated in a series of washes in absolute ethanol 






2.2.4.1.2 – Immunofluorescence assay 
 FPPE tissue sections were placed in the oven at 60°C for 1 ½ hours, de-
waxed in two xylene washes, and hydrated by serial washes in absolute ethanol, 70% 
ethanol and single distilled water. Antigen retrieval was performed by boiling the 
slides in 10mM citrate buffer (pH6) for 25min. Slides were then incubated overnight 
at 4ºC in a solution of 10% Donkey Serum (Sigma), 5% Bovine Serum Albumin 
(Sigma) and 1% Tween diluted in PBS, for non-specific background blocking. 
Blocked slides were washed with PBS and probed with primary antibodies against 
PCNA (1:100, Santa Cruz Biotechnology), FITC-Ki-67 (1:50, Dako) or active 
caspase-3 (1:100, BD Bioscience). After a 4h incubation at room temperature slides 
were again washed in PBS and correspondent secondary antibodies were added to 
each slide (0.5:1000, Jackson ImmunoResearch Laboratories). Secondary antibody 
incubation was performed at room temperature for 25 minutes, after which slides 
were washed with 1% Tween/PBS. Slides were then incubated with 1μg/mL 
DAPI/PBS (Invitrogen) for nuclear staining, washed with PBS, mounted with 
Vectashield mounting medium (Vector Laboratories), and imaged (see section 
2.2.4.5 for details). 
 
2.2.4.1.3 – Immunoperoxidase assay 
 FPPE tissue sections were placed in the oven at 60°C for 1 ½ hours, de-
waxed in serial washes of xylene, absolute ethanol and 96% ethanol, and immersed 
in a solution of 30% H2O2 / methanol for 30min to block endogenous peroxidase. 
Sections were then hydrated in serial washes of 70% ethanol and water, and boiled in 
TEG buffer for 30min. Slides were allowed to cool at room temperature for 30min 
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and then incubated in 50mM NH4Cl for 30min at room temperature. Sections were 
washed with Wash Solution 1 (see section 2.1.5) and probed with KRT18 antibody 
(1:200, Sigma) overnight at 4ºC. After primary antibody incubation sections were 
washed with Wash Solution 2 (see section 2.1.5) and probed with correspondent 
secondary antibody (1:200, Promega) for 30min at room temperature. Slides were 
washed again with Wash Solution 2 and stained with DAB (Sigma) at room 
temperature for 10min. Slides were then washed with PBS and water, counterstained 
with haematoxylin and rinsed in water. Excess die was removed by washing in 
saturated lithium carbonate solution and again in running water. Sections were then 
dehydrated in serial washes of absolute ethanol and xylene, mounted with D.P.X. 
mounting medium (BDH) and allowed to dry overnight before imaging. 
 
2.2.4.2 – Imaging and analysis 
 Brightfield microscopy was performed with Zeiss Axioplan 2 microscope 
with 20x or 40x objectives. 
Fluorescent microscopy was performed with a Zeiss Axioplan 2 microscope 
with 40x or 100x Plan Neofluor objectives and a Chroma 83000 filter set. Each 
channel was recorded independently, and pseudocolor images were superimposed. 
Images were captured using in-house scripts written for IPLab software. 
 Five fields of view per marker per sample were captured “blindly” to remove 
bias. For each marker, the total number of cells and the number of positive cells was 
counted, the percentage of positive cells per field was calculated and the average of 
the five fields determined.  
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 Epithelial cell count was performed on 400x magnification fields of view, 
while quantification of proliferation and apoptosis markers was performed on 1000x 
magnification fields of view. 
 
2.2.4.3 – Immunocytochemistry 
 Cells grown on cover slips and previously fixed were washed with PBS and 
incubated for 30min at room temperature in a solution of 10% donkey serum in PBS 
to block non-specific protein. After incubation this solution was discarded and 
replaced by primary antibodies diluted to 1:100 in 10% donkey serum solution 
previously used. Primary antibody incubation was performed at room temperature for 
2h. Cells were then washed with PBS and correspondent secondary antibody diluted 
to 1:200 in 1.5% donkey serum/PBS solution was added to the wells. Secondary 
antibodies were incubated at room temperature for 30min, after which cells were 
washed in PBS. A solution of 1μg/mL DAPI/PBS was then added to the cells and 
incubated for 5min. Cells were washed again with PBS and slides were mounted 
with Vectashield mounting medium (Vector Laboratories) and imaged as described 
below. 
 The following primary antibodies were used in this assay: Ki-67 (1:100, 
Dako) or active caspase-3 (1:100, BD Bioscience). 
 
2.2.4.3.1 – Imaging and analysis 
Fluorescent microscopy was performed as described in section 2.2.4.2 using a 
65x Plan Neofluor objective. 
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 Ten fields of view per marker per sample were captured “blindly” to remove 
bias, at a magnification of 650x. For each marker, the total number of cells and the 
number of positive cells was quantified, then the percentage of positive cells per field 
was calculated and the average of the ten fields determined.  
 
2.2.4.4 – Western Blot analysis 
 To generate whole cell lysates, cell pellets, collagenase IV digested tumour 
pellets or frozen tumour samples were homogenised and incubated in 1x Lysis 
Buffer (Cell Signalling) supplemented with Complete Protease Inhibitor (40µL/mL), 
Pefabloc (1mg/mL), Pepstatin A (1µg/mL), NaF (1mM), Na3VO4 (1mM) and PMSF 
(1mM) for 30min with vortexing every 10min, then centrifuged at 13000rpm for 
10min at 4°C. Supernatant was transferred to fresh tubes and pellets were discarded. 
Protein concentration was quantified using the Bio-Rad Protein Assay (Bio-Rad) 
according to manufacturer’s instructions. 30µg of protein was loaded on to 10% 
polyacrylamide gels then proteins separated by SDS-PAGE at 160V for ~1½h. 
Proteins were transferred to Polyvinylidene fluoride (PVDF) membranes using a 
semidry blotter (Bio-Rad) at 10V for 30min. Membranes were blocked in 5% 
milk/PBS for 2h at room temperature or 45min at 37ºC, and probed with primary 
antibody diluted in PBS/BSA/Azide solution. Primary antibody incubation was 
performed at 4°C overnight or at room temperature for 1h, depending on 
manufacturer’s instructions. After incubation, membranes were washed in PBS with 
1% Tween, and probed with correspondent secondary antibodies for 1h at room 
temperature. Membranes were finally washed in PBS with 1% Tween and 
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Amersham Hyperfilm ECL films (GE Healthcare) were exposed to the blots for 1-
10min and developed using a Konica-Minolta SRX101A machine. 
Antibodies used for western blotting were: p-p44/42 MAPK (1:1000; Cell 
Signalling), p44/42 MAPK (1:1000; Cell Signaling), p-Akt (1:500; Cell Signaling), 
Akt (1:500; Cell Signaling), p-MEK (1:500, Cell Signaling), MEK (1:500; Cell 
Signalling), p27 (1:100, Calbiochem), CDK4 (1:1000; Cell Signalling), Cyclin D1 
(1:200, Thermo), p21 (1:200, Santa Cruz), CDK1 (1:500, Sigma), CyclinB1 (1:500, 
Cell Signalling) acetylated lysine (1:500, Cell Signalling), Bcl-xS/L (1:200, Santa 
Cruz), TIF1A (1:1000, Assay Biotech) or β-actin (1:2000, Sigma).  
 
2.2.4.4.1 – Western Blot quantification 
 Western Blot quantification was performed using ImageJ software. Band and 
background intensities were measured then band intensity calculated by subtracting 
background values from band values. All protein intensities were normalised using 
β-actin to correct for variability in protein loading. Phosphorylated protein was also 
normalised using corresponding native protein values.  
 
2.2.4.5 – Viability assays 
2.2.4.5.1 – MTT Viability Assay 
MTT viability assays were performed on tumours and outgrowths cultured on 
collagen gels. 20μL of MTT reagent was added to each tumour culture and plates 
were incubated at 37ºC for 4h. The formation of purple formazan crystals indicated 
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viability of the tumours and cell bodies. Cultures were imaged with a Nikon AZ100 
macroscope with 1x magnification objective. 
 
2.2.4.5.2 – Sulforhodamine B viability (SRB) assay 
 Sulforhodamine B viability assay was performed on colorectal cancer cell 
lines to determine cell growth curves, establish EC50 values and evaluate the effects 
of AZD6244 and aspirin individually and in combination. 
 Cells were fixed in 4% TCA for 45min at 4ºC and washed 10x with water and 
dried at room temperature. SRB solution was added to the plates and cells were 
incubated at room temperature for 30min. SRB solution was removed and cells were 
washed 4x with 1% acetic acid, and dried. SRB was then solubilised with a 10mM 
Tris solution (pH10.5), and absorbance was measured at 540nm with a Bio-Tek 
Synergy HT plate reader and Gen 5 software.  
 Cell viability was determined from the average absorbance values obtained 
from 6 experimental repeats performed per assay. As this assay gives an indication 
on the levels of live cells, inverted average absorbance values were used in the 
AZD6244 and aspirin combination treatments to determine the level of cell death as 





























Cancer models play a fundamental role in understanding the processes 
involved in cancer initiation and progression, and are vital instruments for the 
development and testing of new therapeutic agents. However, it is becoming 
increasingly clear that results obtained with the most commonly used cell based and 
animal models of colon cancer don’t always translate to the clinic. Therefore, there is 
a pressing need to develop tumour models that are relevant to the human disease. An 
ideal  model would maintain the tissue organisation and structure, oncogenic 
properties, differentiation functions and cellular heterogeneity presented in vivo 
(168). Ex vivo explant cultures are the only models likely to meet these requirements.  
Literature reporting methods for culturing organ explants dates from the 
beginning of the 20
th
 century when Carrel, in 1912, first reported maintaining 
embryonic heart tissue in culture for a period of 3 months (170). Further reports were 
later on presented by several authors (171-173). However, organ culture remained 
limited to embryonic tissue, possibly because that was the interest of the authors. 
This changed in 1959 when Trowell described a method that allowed the 
“satisfactory histological preservation” of explants from a variety of adult organs for 
6-9 days (174). Despite his success in culturing tissue of various origins, he makes 
no reference to the culture of intestinal explants. These seemed to present increased 
limitations probably due to the complexity of the intestinal morphology and 
physiology, and the possibility of contamination. The culture of normal intestinal 
epithelia was first described by Browning et al (175) and later on optimised by 
Autrup et al (176, 177) who was able to successfully maintain normal intestinal 
mucosa in culture for a period of up to 28 days. To date, other methods have been 
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described in the literature, that are essentially, variations of the protocols described 
by these authors, but including different types of tissue support, such as stainless 
steel mesh, lens or filter paper or Gelfoam sponges, and modifications to the 
culturing media. 
Like explant culture of normal tissues, culture of tumour tissues ex vivo has 
evolved slowly. The culture of neoplastic lesions as organs was first reported by 
Elias et al (178) who, by culturing normal, pre-neoplastic and neoplastic tissue from 
mouse mammary glands discovered that different hormonal supplements were 
required by normal and tumour specimens. Their work demonstrated the importance 
of tumour explant cultures for the study of cancer biology, development and 
progression. In the 1980’s, Freeman et al described a method to culture human 
tumour explants of various origins, including colorectal tumours. The method which 
involved the use of collagen gels for tissue support and media supplemented with 
amino acids and antibiotics, allowed for tumour growth for a period of up to 28 days 
and maintenance of morphological and homeostatic properties (168). This method 
was later on successfully used by the group to study the response of explants from 
different tumour types to an array of therapeutic agents. Their results indicated that 
the method could be used to predict response in the clinic (169). More recently, 
similar methods of culturing human tumours, including colorectal explants that use 
collagen gels or Gelfoam sponges for tissue support and variations to the culturing 
media initially used by Freeman et al have been described in the literature. These 
methods can be used in a variety of applications such as the study of tumour biology 
or response to therapeutic agents.  
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Though scientists have been attempting to grow normal colonic mucosa and 
colonic tumours as organ cultures since the 1960’s, the protocols described have not 
been widely used. The growth of both normal and malignant tissue ex vivo is 
technically and financially demanding, and frequently limited by the availability of 
patient material and associated ethical requirements. However, ex vivo models of 
colorectal cancer present numerous advantages when compared to cell based and 
animal models, the most important being the maintenance of the tumour’s individual 
characteristics and cellular heterogeneity. An ex vivo model of colorectal tumours 
will enable study of the response to therapeutic agents, highlighting pathways and 
molecular markers of sensitivity and resistance that are more relevant to the clinic. 
Such a model will also provide a powerful tool to identify those patients more likely 
to benefit from treatment with a therapeutic agent or combinations of agents.  
 
The aim of the first part of my PhD was to develop a consistent, robust 
method for growing human colorectal tumours in ex vivo culture in our lab so that the 




3.1 – Development of an ex vivo model of human tumour explants 
Prior to the start of my PhD the lab had developed a method for culturing 
explants of normal human intestinal mucosa, based on those described by Browning 
et al and Autrup et al. (175-177). The method was very successful and allowed 
normal mucosa to grow in culture for up to 16 days (Brady et al, Manuscript in 
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preparation). Therefore, I used this protocol as a starting point for developing a 
method to grow colonic tumours.  
Briefly, colorectal tumours obtained at the time of resection were 
immediately placed in medium then transferred to the lab. Here they were washed to 
remove endemic colonic bacterial cultures, cut into 1-2mm
2 
fragments then inserted 
in cuts made at the edges of a sterile stainless steel mesh. The mesh was balanced in 
the centre well of a culture dish containing supplemented Waymouth culturing media 
which had previously been determined by the group to provide optimal results for 
normal colonic mucosa explants. According to Browning et al (175) and Autrup et al 
(176, 177) the presence of 95% O2 significantly increased oxygenation allowing for 
longer culturing periods. As this was shown to be the case with the normal mucosa 
samples cultured in the host lab, I also applied this condition to my tumour explants. 
Tumours were cultured in a chamber with 95% O2 and 5% CO2, and incubated at 
37ºC with gentle rocking. Culturing media was replaced daily, and samples were 
maintained in culture for four days. Similar to normal mucosa explants, the objective 
was to maintain the cultures with constant oxygen supply, and intermittent access to 
humidity and nutrients. 
I found that this method was inadequate to the culture of tumour tissue due to 
the nature of the specimens. Unlike normal mucosa, tumour tissue could not be 
stretched over the mesh and the process of trying to secure the tumour fragments in 
the mesh caused great damage to the tissue, often even disintegrating it. Also, tumour 
samples differ greatly in their consistency, and while soft, mucous rich fragments 
were relatively easy to insert in the mesh; solid, fibrous fragments could not be 
firmly attached without damage, and would eventually become free from the mesh 
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due to the rocking movements. I attempted to grow four tumours using this method, 
but quickly concluded that it was unsuitable due to these technical difficulties.  
The stainless steel support provided to the normal mucosa samples was an 
inorganic material that was not likely to interact with the tissue. Regardless of this 
explants grew supported by their own microenvironment. I therefore hypothesised 
that tumour explants could also grow supported by their own stroma only. To test 
this hypothesis, I simply immersed the tumour fragments in supplemented 
Waymouth media under the same culturing conditions. Three tumours were cultured 
using this method. Samples were collected after 24h, 5 days, 10 days and 16 days in 
culture, paraffin embedded, then sectioned and H&E stained. Five fields of view 
were captured for each section (one section per sample) then the number of epithelial 
cells per field counted and the average calculated (see materials and methods for 
quantification details). The results obtained with the first sample cultured show a 
clear, time dependent reduction in the number of epithelial cells, with the most 
dramatic decrease being observed in the first 24h (Figure 3.1). Morphological 
analysis also showed continuous loss of tissue morphology through time in culture in 
all samples cultured using this method (Figure 3.1). These results suggested that 
tissue was being damaged by direct contact with forceps in the process of daily 
















Figure 3.1: Tumour morphology is not maintained through time in culture 
due to dramatic decrease in the number of epithelial cells. H&E stained 
sections of a tumour cultured for up to 16 days using the floating method 
(bottom) show that original morphology was not maintained through time in 
culture. Loss of morphology resulted from the dramatic decrease in the total 
number of epithelial cells observed as early as 1 day in culture and thereafter, 
as shown in the graph (top). Data was obtained from 5 fields of view captured 
per time point. One tail Student’s t test was used to calculate p values. 
Epithelial cells were identified according to their typical morphology as shown 
in H&E stained sections.  
73 
 
3.1.1 Evaluation of tissue support platforms: filter paper 
One problem with the above method was that the daily transfer of tissue 
fragments into new medium caused mechanical damage to the tissue. Based on this 
evidence and on the results previously obtained by the group with normal mucosa 
samples, I hypothesised that the use of an inert tissue support platform would work 
as a raft for the daily transfers to new culture dishes, but also as a structure to which 
the tumours could attach to and grow.  
Previous reports had suggested that lens or filter paper could be used as a low 
cost and effective support platform to allow the growth of normal and malignant 
tissues ex vivo (179-181). Hearn et al showed that embryonic intestinal tissue 
cultured on filter paper support was viable for up to 10 days with maintenance of 
morphology and differentiation patterns evidenced by the expression of typical 
markers (179), and Yarnell et al described a method of culturing tumour biopsies that 
included floating rafts of lens paper for tissue support and maintenance of the 
cultures in pressurised chambers (181). Therefore, I proceeded to culture the tumours 
under the conditions previously used, but on filter paper rafts so that daily transfer to 
a new culture dish could take place without mechanical damage, and so that the 
tumour explants could be maintained on a support. In total, ten tumours were 
evaluated for their ability to grow on filter paper disks. Each tumour was divided into 
a maximum number of 10 pieces (dependent on original size). The tumour fragments 
were then placed individually on filter paper disks and immersed in media in the 
centre well of the dish. I continued to use the supplemented Waymouth media that 
had been successful for growing normal mucosa. I also continued with the 
oxygenation and media replacement regime. I hoped that, using these growth 
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conditions and providing the tumours with a support would allow the re-growth 
observed in normal mucosa. Samples were harvested after 0, 1, 5, 10, 16, 20, 24 and 
30 days of initial plating, fixed then paraffin embedded. The number of data points 
per tumour was dependent on the initial size of the sample. 
To investigate culture effects on tumour growth and morphology, H&E 
stained sections were analysed and the number of cells epithelial cells per field of 
view was quantified as above.  These data clearly demonstrated that there is a time 
dependent decline in the number of epithelial cells in the sample, and that this 
decline is most abrupt within the first 24h in culture. H&E stained sections also show 
considerable loss of tissue morphology especially at later data points (Figure 3.2).  
To further analyse cell growth and death in culture, immunohistochemistry 
was performed on tissue sections using the proliferation marker Ki-67 and apoptosis 
marker active caspase-3. Interestingly, I found that even though there was a rapid 
decrease in the number of epithelial cells in the samples after 24h in culture, there 
was no change in the percentage of proliferative cells (Figure 3.3b). However, there 
was a significant increase in the percentage of cells positive for caspase-3 (Figure 
3.3d). These data would suggest that upon plating on filter paper, a large number of 
epithelial cells undergo apoptosis, which results in cell loss, but the remaining cells 
continue to proliferate. 
Since hypoxia has been shown to contribute to tumour growth (182, 183), one 
tumour was cultured in parallel under high and low oxygen conditions. Sample 
performance in culture was evaluated by H&E and immunohistochemical analysis as 
described above. Analysis of the number of epithelial cells at each time point, 
obtained from H&E stained slides, showed no difference between samples cultured 
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in the presence of high or low oxygen levels. Both groups displayed the same 
dramatic decrease in the number of epithelial cells after 24h in culture and thereafter 
(Figure 3.4). Analysis of proliferation marker Ki-67 also showed no difference 
between the two groups. In both sets, Ki-67 expression remained stable for 24 hours 
then dropped considerably after 5 days in culture (Figure 3.4).  
In contrast to Ki-67, I found that, at least in this one sample, growth under 
hypoxic conditions dramatically increased the level of apoptosis, as indicated by 
increased number of cells staining positive for active caspase-3 after 1 day in culture 
(Figure 3.4). I concluded from these data that, even though the sample number was 
small, growth in hypoxic conditions is unlikely to reverse the initial cell death/loss 
observed when tumours are grown on filter paper. 
From this set of data I concluded that the filter paper method, despite 
presenting a solution for the minimisation of damage caused by the daily changes to 
a new culturing dish, does not provide the requirements for tissue growth. The loss of 
typical morphology through time in culture indicates that the method does not 
contribute to the maintenance of tissue microenvironment leading to continuous 
tissue degeneration. Also, the high initial levels of apoptosis make it inadequate for 
drug testing as it would be difficult to ascertain whether apoptotic levels would be 











Figure 3.2: Histological analysis of tumours cultured with filter paper 
support. H&E stained sections show loss of original morphology in a tumour 
cultured on filter paper for up to 20 days (Bottom). Graph shows the 
decrease in the number of epithelial cells observed at 1 day in culture and 
thereafter in ten samples cultured using this method (Top). Images were 
captured from 5 independent fields of view per time point per tumour and the 
number of cells quantified. Epithelial cells were identified according to their 
typical morphology as shown in H&E stained sections. Data presented are 
the pooled results for all tumours (Average of T0, n=10; 24h, n=7; 5 days, 
n= 10; 10 days, n=5; 16 days, n=4; and 20 days, n=2 +/-SE). One tail 










Fig. 3.3: Proliferation and apoptosis rates in samples cultured with filter 
paper support. Figures (a) and (c) show examples of sections stained for 
proliferation marker Ki-67 (a) and apoptosis marker active caspase-3 (c). 
Images were captured at a magnification of 1000x. Image (a) shows a field of 
view with a large number of Ki-67 positive cells which can be easily identified 
in the single channel image on the right. Image (c) shows a field of view with 
only one clearly positive active caspase-3 cell. Single channel image on the 
right confirmed positive staining. The percentage of positively stained cells for 
each marker was quantified from 5 fields of view per tumour per time point. 
Quantification results are shown in graphs (b) and (d). Data are the average 
for T0, n=10; 24h, n=7; 5 days, n=10; 10 days, n=6; 16 days, n=4; 20 days, 














Figure 3.4: Lower O2 conditions did not improve the performance of a 
tumour cultured with filter paper support. Top graphs show histological 
analysis of the number of epithelial cells in one tumour sample cultured in 
parallel on filter paper with high and low oxygen supply. Decrease in the 
number of epithelial cells through time in culture has occurred in a similar 
fashion in both groups of samples. The same is observed for proliferation 
marker Ki-67. However, expression of apoptosis marker active caspase-3 
seems to indicate that, contrary to what was expected, samples performed 
better under high oxygen conditions. Data was obtained from 5 fields of view 
per sample per time point. Data are the average of T0, n=2; 1 day, n=2; 5 
days, n=2 +/- SE. 
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3.1.2 Evaluation of tissue support platforms: collagen gels 
 As the use of filter paper as a tissue support platform proved unsuccessful for 
the maintenance of tissue morphology and homeostasis, I hypothesised that a type of 
tissue support that better resembles the tumour microenvironment found in vivo 
would contribute to the maintenance of tissue integrity and allow for growth. 
The importance of the extracellular matrix in cell growth, differentiation and 
survival has long been established. Though the nature of the relationship between 
cells and extracellular matrix varies with the type of cell, adhesion between cells and 
the extracellular matrix is fundamental for the establishment of signalling routes that 
determine cell behaviour (184). For example, in a variety of cell types, including 
intestinal epithelial cells, loss of adhesion to the extracellular matrix rapidly induces 
apoptosis (185). The extracellular matrix is mainly composed of collagen which 
accounts for 90% of its dry weight in most tissues, and of which type I is the most 
common (186).  
The successful use of collagen gels in ex vivo culture systems of different 
types of tissue has been described by several authors (168, 187-190), including 
Vescio et al and Willson et al who, in two independent publications, reported the use 
of this tissue support platform in long term culture of colorectal tumour tissues 
obtained from patients (169, 191). Therefore, my next approach was to culture the 
tumour explants using type I collagen gels for tissue support. Briefly, 1-2mm
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tumour fragments were placed individually on commercially obtained type I collagen 
gels previously set in 24-well plates, and covered with supplemented media. As the 
method used to culture normal mucosa had not been successful for tumours, I 
reverted to culturing the tissue using a method described in the literature in which 
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Waymouth media was replaced with MEM, and instead of incubation in a pressure 
chamber with controlled O2 levels, tissues were incubated with 5% CO2. Tumours 
were cultured at 37ºC as previously, but without rocking. 
To evaluate tumour growth, ten samples were cultured using this method. 
H&E stained sections of tumour samples show that typical morphology is maintained 
for up to 12 days in culture (Figure 3.5), and immunostaining with epithelial cell 
marker KRT18 (192) shows that even though the number of epithelial cells 
drastically decreases in the first 24h in culture, it remains constant thereafter (Figure 
3.5) suggesting that samples undergo a period of adjustment to the new environment 
after which they stabilise. This notion is also supported by the results obtained with 
proliferation marker Ki-67 and apoptosis marker active caspase-3 (Figure 3.6). The 
proliferative rates greatly decreased after 24h in culture but became constant after 
day 5, which coincides with the pattern observed with the epithelial cell marker 
KRT18. The increase in the number of apoptotic cells in the first 24h in culture 
followed by a drastic decrease at 5 days also reflects the number of epithelial cells 
during this period (Figure 3.6). 
Histological and immunohistochemical data obtained with this set of tumours 
clearly demonstrated that the number of epithelial cells decreased through time in 
culture indicating that growth has not occurred. However, data also suggests that, 











Figure 3.5: Histological analysis of tumours cultured using collagen gel 
support. Top figures show examples of H&E stained sections of the same 
tumour at indicated time points. Bottom figures show tissue sections of the 
same tumour at different time points stained for epithelial cell marker KRT18. 
Images were captured at 400x magnification. Graph shows the variation in the 
number of epithelial cells through time in culture. Five fields of view were 
captured per sample, per time point, and the number of KRT18 positive cells 
quantified. Data shown are the average of T0, n=6; 24h, n= 2; 5 days, n=5; 7 
days, n=4; 12 days, n= 4; 16 days, n=4; 28 days, n=2; 35 days, n=2; and 47 












Figure 3.6: Proliferation and apoptosis in tumours cultured using 
collagen gel support. Top: graph shows the percentage of Ki-67 positive 
cells per field of view per time point. Bottom: graph shows the percentage of 
active caspase-3 positively stained cells per field of view through time in 
culture. For each marker five fields of view per time point per sample were 
analysed. Data presented here are the average of all tumours collected for 
each time point: T0, n= 6; 24h, n=2; 5 days, n=6; 7 days, n=5; 12 days, n=4; 
16 days, n=4, and 28 days, n=3, +/- SE). One tail Student’s t test was used to 
calculate p values. Data indicates that explants stabilise in culture after an 




I consistently observed the formation of cell outgrowths from the tumour 
when they were placed on collagen gel beds. This occurred in a time dependent 
manner and was evident from as early as 24h after plating in the vast majority of the 
explants. Generally, the number of cells invading the collagen gels increased in 
number over several days. An example is shown in Figure 3.7. Similar outgrowths of 
tumour cells had been observed within the institute when breast cancers were placed 
on collagen beds and it was believed that these outgrowths represented an example of 
invasive tumour. Furthermore, similar observations were previously reported by 
Freeman et al (168). 
These data were particularly interesting as they suggested that although the 
main tumour body was not growing, cells were invading into the medium. I 
hypothesised that this cell invasion/growth may act as a good model for tumour 
growth. Therefore, I proceeded to characterise the nature of the outgrowths. 
 
3.1.3 Characterisation of tumour outgrowths  
Eight tumour samples were cultured on collagen gels as described above, 
with the objective of characterising the tumour outgrowths, and exploring the 
therapeutic potential of this model. Tumour fragments were plated onto collagen gels 
as above then each fragment was imaged prior to harvest and at 0, 1, 2, 5, 7, 16 and 

















Figure 3.7: Formation of outgrowths observed in tumours cultured on 
collagen gels. The figure shows two examples of tumour samples grown on 
collagen gels (A and B). Images were captured at indicated times while still 
in culture (1x magnification). In A, formation of outgrowths was observed 2 
days after plating with continuous increase in number and size through time 
in culture. By day 7, the main body of the tumour also appears to have 
grown. In B, clear outgrowth formation was only observed at day 5, but 
occurred in a much more dramatic fashion than in A. C shows zoomed in 
images of the outgrowths observed in B. These were clearly moving from 
the tumour onto the gel. 
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These data demonstrated that in all 8 tumour samples, cell aggregates grew 
from the tumour into the collagen matrix in at least one fragment cultured. In 75% of 
tumours all fragments cultured displayed this phenomenon. In total, 165 tumour 
fragments were placed in culture for this series of experiments and I found that cells 
grew out the tumour to visually form growths in the matrix in 148 of these 
fragments. This represents 89.6% of all tumour fragments. However, the degree of 
outgrowth formation varied from tumour to tumour, but also within the same tumour. 
Qualitative analysis of the density and size of the outgrowths revealed different 
patterns of growth on to the gels. The outgrowths were then graded into four 
different categories according to these patterns and the number of wells displaying 
each grade was quantified. Wells that displayed a small number of outgrowths of 
reduced size scattered onto the gels were classified as grade 1. Wells that presented a 
large number of small outgrowths and few larger ones scattered onto the gel were 
classified as grade 2. Wells that presented large outgrowths occupying ~75% of the 
gel area were classified as grade 3, and wells that presented very large outgrowths 
that fully covered the whole area of the gel were classified as grade 4. Figure 3.8 
shows examples of different grades observed, and how frequently they occurred.  
To investigate the origin and nature of these structures, I initially tried to fix 
and embed the cell outgrowths and the collagen gels. However, this proved difficult 
due to the small size of the cell bodies and the fragility of the collagen gels. 
Therefore, I proceeded to digest the collagen gels with collagenase IV to fully release 
the cell bodies from the gels. I then extracted protein so that outgrowths could be 














Figure 3.8: Grade of outgrowth formation and frequency. Top – figure 
shows examples of each grade of outgrowth formation observed. Images were 
obtained from different wells at 7 days in culture using a Nikon AZ100 
macroscope at 1x magnification. Qualitative analysis of the density and size of 
the outgrowths revealed distinct patterns of growth on to the collagen gels. 
The number of wells displaying each grade was counted. The graph (bottom) 




At the point of harvest, the main body of the tumour was also removed from the 
collagen gels and immediately frozen for protein extraction and western blot 
analysis. To determine whether the observed tumour outgrowths were of epithelial 
nature, I performed western blot analysis with antibodies to EpCam (Epithelial cell 
adhesion molecule). This is a type I membrane glycoprotein exclusively expressed in 
epithelial tissues and epithelia derived neoplasms. It is involved in a variety of 
processes such as signalling, cell migration, proliferation and differentiation (193, 
194). EpCam expression is greatly increased in rapidly proliferating tumours but 
reduced in normal tissues (195). The protein can occur in 4 distinct forms (34-
40KDa) as a result of differential glycosylation. The glycosylation pattern of EpCam 
is reported to be tumour specific (196, 197). 
Firstly, I found that in all cases, EpCam was detected in protein extracted 
from tumour outgrowths, suggesting that epithelial cells were present in this 
population. When analysing the pattern of EpCam expression, I found that there were 
multiple EpCam bands at T0 but after 24h in culture only one rather intense band of 
smaller size was detected, indicating that the glycosylation status of the protein had 
changed as a result of the culturing conditions. At later data points, another larger 
band of ~60kDa was observed in some samples, suggesting further changes to the 
protein. Importantly, these patterns of EpCam expression were observed in both 
tumour bodies and outgrown cells, suggesting the two populations had a common 


















Figure 3.9: Pattern of expression of EpCam suggests that cell 
outgrowths are of epithelial origin and derived from the main body of the 
tumour. Figure shows western blot analysis of epithelial cell marker EpCam in 
main tumour body and cell outgrowths of two tumour samples (A and B). 
Western blot analysis was used to compare the levels, and post-translational 
status of the epithelial cell marker EpCam in the main body of the tumour 
versus the outgrowths. Figure demonstrates that the marker is detectable in 
outgrown cells, and that the post-translational status in these structures 
parallels that of the main tumour body. T0 sample is the same in tumour body 
and outgrowth gels. 
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To confirm these data, western blot analysis was performed using the 
epithelial cell marker, KRT18. In contrast to the results obtained with EpCam, I 
found that KRT18 could not be detected in outgrown cell samples, while this was 
readily detectable in samples from tumour bodies (Table 3.1). Given that KRT18 
expression is reported to be higher in differentiated epithelial cells (198) while 
expression of EpCam is inversely correlated with differentiation (199) the 
discrepancy may suggest that the outgrown epithelial cells are less differentiated and 
more aggressive than tumour epithelial cells.   
Based on the EpCam results, I concluded that the tumour outgrowths were 
epithelial in nature and were behaving like the epithelial cells in the main tumour 
body once in culture. Next, I wished to determine whether the outgrowing cells were 
viable. In order to do this I performed MTT assays. MTT reagent, a tetrazolium salt, 
is incorporated and reduced to formazan by live cells only, causing a change in 
colour of the reagent (200). MTT reagent was added to the culturing media and 
cultures were incubated for 4h at 37ºC. Changes in colour were recorded with 
macroscopic imaging. Results show that, in four tumours analysed, outgrowths 
remain viable in culture up to at least 1 day (Figure 3.10). 
Based on the consistency with which tumour outgrowths were observed, my 
data suggesting that they were of epithelial nature and the data showing they were 













Table 3.1: Expression of epithelial cell markers KRT18 and EpCam. Table 
shows the summary of the results obtained with western blot analysis for 
epithelial cell markers KRT18 and EpCam in four tumour samples at different 
time points in culture. (+) indicates the presence of bands while (-) indicates 
the absence of bands of each marker. While EpCam expression is similar in 




















Figure 3.10: Cell outgrowths from the main tumour are viable after 1 
day in culture. MTT assay performed on a tumour sample cultured on 
collagen gels after formation of outgrowths. The pink colour of the MTT 
reagent indicates that outgrown cells are viable. 
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3.1.4 Collagen gel support: the potential for testing therapeutic drugs 
My previous data suggested that this model may be suitable for testing the 
response of patient tumour explants to different therapeutic agents. To test this 
suggestion, I firstly utilised aspirin as a model anti-tumour agent. The group in which 
my PhD was undertaken have been working on the mechanisms by which aspirin 
acts against colon cancer cells for a number of years (133, 201). Therefore, the 
timing of aspirin events and a number of specific markers of aspirin response are 
known. Furthermore, this agent is known to inhibit proliferation and mediate 
apoptosis of a wide range of colorectal cancer cells in vitro (133), acting 
independently of the mutational status of the cancer (202).  
I hypothesised that agents that inhibit tumour growth may inhibit 
proliferation/mediate apoptosis of outgrowing cells, thus blocking outgrowth 
formation. In order to test this hypothesis, five tumour explants were plated in 
collagen gels as above. At the point at which the outgrowths were apparent (24-48h), 
cultures were treated with aspirin (0-10mM) for 4-6 days. Following harvest, western 
blot analysis was used to examine specific markers of aspirin response in the main 
body of the tumours and in outgrown cells, as above. However, the data obtained 
from this series of experiments were inconclusive. I found that it was technically 
very challenging to perform western blot analysis on the outgrown cells (before and 
after treatment) as cell numbers were small giving very low protein yields. I also 
found that the markers of aspirin response analysed, Cyclin D1 and IκB, were not 
expressed in all tumours (data not shown). While this was interesting, it did not allow 
for aspirin response to be determined.  
93 
 
Due to the difficulties in working with outgrown cells, I next tested aspirin 
effects on the main tumour bodies using an alternative protocol. I hypothesised that if 
tumours were treated immediately after plating, increased apoptotic rates as a result 
of treatment could be measured, and typical markers of response would still be 
expressed at detectable levels. Therefore, I proceeded to treat tumour samples at time 
0 (initial plating) for 24h only. Eight tumours were treated using this method. 
Immunohistochemical analysis with antibodies to active caspase-3 
demonstrated that, as had been previously observed (see 3.1.2), the tumours 
underwent catastrophic apoptosis within the period of the experiment (compare T0 
and 0uM in Figure 3.11a). Furthermore, treatment regimes did not significantly 
increase these rates. A lack of a significant dose responsive effect of the agent on cell 
proliferation and apoptosis can be seen in individual tumours (data not shown) and if 
data from all tumours is combined (Figure 3.11a). Western blot analysis 
demonstrated that aspirin, which is an acetylating agent, induced a dose-dependent 
increase in total protein acetylation, confirming penetration of the drug into the 
tumour (Figure 3.11b). Decreased levels of Cyclin D1 is an early marker of aspirin 
response (see Introduction) (135). However, there was minimal change in the levels 
this protein (Figure 3.11c). In keeping with my immunohistochemistry results, 
western blot analysis indicated that aspirin had little effect on levels of proliferation 
or apoptosis, as indicated by the markers PCNA and pro-caspase-3 respectively 

















Figure 3.11: Markers of response to aspirin treatment. (A) 
Immunohistochemistry for Ki-67 and active caspase-3 used to examine the 
effect of the agent on proliferation and apoptosis, respectively, in tumour 
samples treated for 24h with aspirin in dose response studies. Five fields of 
view were captured per sample per concentration, and the average number of 
positive cells for each marker was quantified. Data shown are the pooled results 
for five tumours +/- SE. One tail Student’s t test was used to calculate p values. 
An asterisk (*) above the data point indicates p≤0.05. (B) Western blot analysis 
showing protein acetylation as a result of aspirin treatment in tumours. Protein 
acetylation is clear in samples treated with 3-10mM aspirin. (C) Western blot 
analysis was used to examine aspirin effects on known marker of response, 
Cyclin D1. Image J analysis used to quantify intensity of bands on western blots 
indicated no significant change in Cyclin D1 levels in response to aspirin. Data 
shown are the pooled data for five tumours for each dose. One tail Student’s t 
test was used to calculate p values. An asterisk (*) above the data point 
indicates p≤0.05. (D) Western blot analysis of apoptosis marker Pro-caspase-3 
and proliferation marker PCNA. Expression of both markers remained constant 
in response to aspirin. 
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To determine whether this lack of response was due to the agent, or a failing 
of the model, I next tested Oxaliplatin. This agent is routinely used in the clinic as a 
therapy for colorectal cancer and has previously been shown to induce cell death in 
colorectal cancer cell lines (203). Oxaliplatin induces cell cycle arrest at the G1-S 
phase of the cell cycle caused by a decrease in expression of Cyclin B and CDK1 
(204). Three tumours were treated with 0-10μM of the agent. Western blot analysis 
indicated that the agent induced minimal change to the levels of these markers in all 
3 tumours analysed. In keeping with a lack of response to the agent there were 
minimal changes to levels of PCNA and pro-caspase 3 (Figure 3.12). 
Taken together, these data would suggest that this method of tumour growth 
is not appropriate for therapy testing without substantial further optimisation.  
 
3.1.5 – Culturing of human colorectal tumours: spheroid cultures 
 The use of multicellular tumour spheroids in cancer research has been 
reported in the literature for nearly 40 years. Multicellular tumour spheroids obtained 
from human cancer cell lines are used as an alternative to monolayer cultures to 
study the regulation of tumour cell physiology and therapeutic responses in a 3D 
context (205, 206). Multicellular spheroid cultures can also be obtained from normal 
intestinal mucosa from mice (207, 208), or from human normal intestinal epithelia 
(163, 187). These systems enable the study of proliferation, migration and 
























Figure 3.12: Markers of response to Oxaliplatin treatment. Western Blot 
analysis of apoptosis marker Pro-caspase-3 and proliferation marker PCNA 
in samples treated with increasing concentrations of oxaliplatin for 24h. Data 
shows a lack of dose responsive effects of oxaliplatin.  
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Multicellular tumour spheroids obtained from disaggregated human colorectal 
tumours have also been reported, and despite some controversy regarding the 
spheroid ability to reproduce the tumour’s original in vivo environment and maintain 
it’s individual characteristics, these systems have shown potential as models to study 
different aspects of tumour biology and response to therapeutic agents (161, 162). 
Therefore, I next used the protocol recently described by Kondo et al. (161) to grow 
spheroids from human tumour samples. 
Briefly, patient tumours obtained at the time of resection were immediately 
transferred to the lab, washed and minced. Minced tissue was then washed by 
centrifugation and re-suspended in supplemented MEM media containing 
collagenase IV. Tissue was incubated at 37ºC for 2h with vigorous rocking. After 
digestion with collagenase IV, samples were filtered through a stainless steel mesh 
with a pore size of approximately 500μm and then passed through a 40μm cell 
strainer to remove smaller fragments, washed by centrifugation, re-suspended in 
supplemented stem cell media and cultured at 37ºC with 5% CO2. Fresh media was 
added to the cultures every other day. Spheroid formation was monitored using a 
confocal microscope.  
Six tumour samples were cultured using this method and consistent formation 
of spheroids of different sizes (Figure 3.13) was observed in all samples following 
24-48h in culture. However, four of the samples cultured were discarded after 48h 
due to the presence of contamination. Expansion of the spheroid cultures to 24-well 
plates containing previously set type I collagen gels was attempted with one of the 














Figure 3.13: Multicellular tumour spheroids. Images show tumour 
spheroids obtained from disaggregated fresh colorectal tumour tissue and 
cultured in supplemented stem cell media for 1 (left) and 2 (right) days. 
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However, re-setting into collagen gels appeared to stop the growth of the spheroids. 
Instead I found that simply splitting the cells to new culturing dishes containing 
supplemented MEM was enough to stimulate the formation of new spheroids, and 
the growth of existing ones. One of the tumours was expanded in culture for several 
weeks using this method. Surprisingly, I observed that in culture dishes that did not 
have the medium replenished the spheroid number was increased. This was possibly 
due to the increased proximity between spheroids or increased concentration of 
signalling molecules in the media. It may also be that lack of nutrients and oxygen 
supply stimulated tumour growth. Splitting of these cultures into fresh media did not 
result in further growth, though spheroids appeared viable during the whole period in 
culture. 
Despite the fact that this method appeared extremely promising, I did not 
proceed to test its potential in drug response assays. Further use of the method would 
require characterisation of the spheroids to ascertain if the tumour’s individual initial 
features were maintained and for how long, and the development of new methods of 
analysis. At this point in my PhD, I could not afford to pursue a method that may 
ultimately not be suitable, as the previous methods had not been. 
 
Discussion: 
The development of an ex vivo model of human colorectal tumours proved to 
be extremely challenging and time consuming. The initial culturing method, adapted 
from the protocol used to grow normal intestinal mucosa, and the floating method, 
showed that normal and malignant tissues have different growth requirements. The 
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floating method also indicated that colorectal tumour cultures require a support 
platform with which the tissue can interact with and grow.  
The use of lens or filter paper as a support platform for tissue growth was 
previously described in the literature. Yarnell et al (181) described a method with 
which tumour biopsies were cultured on lens paper support floating over culturing 
media supplemented with antibiotics, amino acids, glucose and 10% calf serum, and 
incubated in a sealed chamber containing 5% CO2. The group were able to maintain 
cultures of myxofibrosarcoma of the thigh for 48h, and use the model to study 
response to therapeutic agents, methotrexate and melphalan. Similarly, Hearn et al 
(179) reported the long term growth of embryonic intestinal tissue from mice on 
filter paper support platforms immersed in media supplemented with antibiotics, 
amino acids and 10% foetal calf serum, and incubation with 5% CO2 with media 
changes every two days. Based on these reports, I hypothesised that colonic tumours 
could be grown on filter paper rafts for extended periods of time, but even though I 
used culturing conditions very similar to those described by these authors, tissue 
growth was not observed in any of the tumours cultured. This could be due to the 
daily media changes, which continuously depleted the cultures from signalling 
molecules; and the rocking movements which prevented the tissue from attaching to 
the filter paper. These conditions were not used by Yarnell et al or Hearn et al, but 
were maintained in my cultures based on the results previously obtained in the lab 
with normal mucosa samples.  
Interestingly, Yarnell et al were only able to maintain tumours in culture for 
48h which is not far from the results obtained with my panel of tumours grown on 
filter paper support, and might explain why the group did not continue to use the 
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method and later on moved on to cultures on agar gels (209). The method described 
by Hearn et al was successfully used in other publications and applied to the study of 
several aspects of gastrointestinal biology (210, 211). These reports indicate that the 
filter paper method is appropriate to the culture of normal intestinal epithelia but not 
ideal for the culture of malignant tissues. 
My next approach was to grow the tumours on collagen gel beds in order to 
provide a support platform that better resembled the tumours in vivo environment. I 
followed a protocol described by Freeman et al (168) in which tumours were 
dissected and placed on previously hydrated collagen gels then covered with MEM 
media supplemented with antibiotics, amino acids, glutamine and 10% foetal calf 
serum. The method allowed for the growth of tumours of various origins including 
lung, colon and breast carcinomas for up to 28 days, during which the formation of 
outgrowths from the main tumour body on to the gels was observed. Similarly, the 
formation of outgrowths from the main tumour on to the gels was also observed in 
my panel of tumours grown on collagen gels. This indicated that cells were either 
growing or migrating from the main tumour body. As tumours are comprised of both 
epithelial and stromal cells, outgrowths could have originated from either source. 
The outgrown cells showed strong expression of EpCam which would not be 
detected in cells of stromal origin. Furthermore, the glycosylation status of this 
EpCam resembled that of EpCam in the original tumour. Therefore, I concluded that 
the cells were of epithelial origin. Unfortunately, low protein concentrations, and 
difficulties in fixing and embedding the cell outgrowths limited further assessment of 
the nature of these structures. Ideally, I would have used markers such as Vimentin 
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(a type III intermediate filament that can be used to identify fibroblasts (212, 213)) to 
determine if a stromal cell population was also present in the outgrowing cells. 
Another question that remains unanswered is whether outgrown cells were 
growing out of the main tumour body or migrating, the latter could in part explain 
the decline in the number of epithelial cells in the main tumour. However, assessing 
for the expression of invasion markers like Laminin 5 (214) or matrix 
metalloproteases (215), and Snail and E-cadherin which are involved in the epithelial 
to mesenchymal transition (216) was also limited by the factors mentioned above. 
The use of a cytospin system and subsequent immunostaining with these markers 
was also proposed, but this was limited by the fact that outgrowths originated from 
patient tissue and had to be handled in a Control Level 2 laboratory. I also attempted 
to use tracking dyes, and live imaging of the cultures but these assays also presented 
a few technical limitations. 
Vescio et al (169) previously demonstrated that tumour tissue grown on 
collagen gels could be used to investigate the response to a variety of therapeutic 
agents, amongst which cisplatin and 5-flurouracil. The group investigated therapeutic 
effects in 20 major classes of tumours, including colon, and found that sensitivity 
patterns of various tumour types were similar to those found in vivo. Based on this 
and on the observations made with my panel of tumours cultured on collagen gel 
beds, I proceeded to test the potential of this model in therapeutic response assays. 
However, I found that I could not detect a pattern of response to treatment with 
aspirin or oxaliplatin in my panel of tumours which indicated that the use of this 
model required further optimisation.  
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One optimisation procedure that could have been tested was the use of tissue 
slices instead of tumour fragments, as described by Vaira et al (167). This method 
would allow for better oxygenation and access to nutrients which could have 
stimulated explant growth. However, the culture of tumour slices was limited by the 
lack of access to a microtome capable of sectioning fresh human tumour samples. 
The use of other types of tissue support like Gelfoam sponge as described by Pirnia 
et al (217) was also considered. However, the use of Gelfoam sponge required a 
medical prescription. Maintaining the cultures in media supplemented with growth 
factors would be likely to increase proliferation rates strongly contributing to the 
tissue regeneration that I aimed for, however the cost of these supplements was an 
important limiting factor. One cheaper and readily available option that could have 
also been tested was the use of DMSO as described by Autrup et al (176, 177). The 
presence of DMSO could have increased access to nutrients by facilitating diffusion, 
and it could also have contributed to tissue preservation. The use of DMSO might 
have also facilitated the absorption of aspirin and oxaliplatin improving response to 
treatment with these therapeutic agents. In summary, various culturing conditions 
could have been attempted, but ultimately, time and continuous access to patient 
material which would have allowed for such conditions to be tested, presented the 
strongest limiting factors.  
 
The results obtained with multicellular tumours spheroids suggested that this 
protocol could provide a reproducible and robust method for culturing colorectal 
tumours. Multicellular spheroids were obtained from all tumours cultured; and for 
one tumour, spheroids continued to form and grow after a number of passages, and 
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were maintained for several weeks. Thus, the use of this system would allow a much 
wider window for drug testing and other applications. Interestingly, observations 
made on this sample suggested that tumour tissue, or at least multicellular tumour 
spheroids would grow better under nutrient starvation and possibly hypoxic 
conditions, factors that are also present in the in vivo tumour environment. Proximity 
between the spheroids might also have contributed for the success of these cultures.  
Despite being a promising method, culturing the tumours as multicellular 
spheroids also required further optimisation of the analysis methods so that full 
characterisation of the spheroids could be performed prior to testing the response to 
therapy. Morphological analysis to confirm the maintenance of tumours original 
features would have to be performed, and though it is possible to fix and embed the 
spheroids, the protocols in place would have to be adjusted to the small size of these 
structures. Once the maintenance of the tumour’s individual characteristics was 
established, response to therapy could be assessed by immunohistochemistry, 
western blot analysis, and by assessment of spheroid growth in the presence and 
absence of drug. As proceeding with these optimisation assays could take several 
weeks or even months, the use of this protocol was halted.   
In summary, 47 patient tumour samples were cultured using different 
methods based in the literature and adapted to the conditions in our laboratory (Table 
3.2). Due to the limited success in growing colorectal tumour explants and the 
requirement for further optimisation of the methods used, I opted to use acute 



















































































































































































































































































































As outlined in the main introduction, mutations in KRAS and BRAF 
members of the MAPK pathway occur in more than 50% of colorectal cancers (98). 
These mutations are mutually exclusive and lead to constitutive activation of the 
MAPK pathway promoting tumour proliferation and survival (96, 100). Targeting 
the pathway downstream of KRAS and BRAF is therefore a promising therapeutic 
option. 
AZD6244 is a highly selective allosteric and non ATP competitive MEK1/2 
inhibitor with reported nanomolar activity against purified enzyme (112, 113). 
AZD6244 has completed Phase I and II clinical trials in a variety of tumour types, 
and it has been suggested for Phase III trials in Ras-mutated non-small cell lung 
carcinoma (218). With a Maximum Tolerated Dose of 100mg bid (twice daily) this 
agent has relatively low toxicity with rash and fatigue being the most commonly 
observed side effects. Treatment with AZD6244 fully inhibits ERK1/2 
phosphorylation in lymphocytes from 12-O-tetradecanoylphorbol-13-acetate-treated 
whole blood used as a surrogate for tumour tissue within one hour of treatment (115, 
118). However, disease stabilisation is generally reported as the best outcome, and 
criteria to identify patients that might benefit from treatment is still to be determined 
(115-118). 
The mechanisms of response to AZD6244 have been extensively studied in 
cell lines and xenograft models. Studies developed in colorectal cancer cell lines 
show that treatment with AZD6244 can induce dose-dependent inhibition of ERK1/2 
phosphorylation and consequent cell cycle arrest at G1 as evidenced by a decrease in 
Cyclin D1/CDK4 expression, and an increase of cell cycle inhibitors p21 and p27 
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(95). These studies also report a wide range of sensitivity to the anti-proliferative 
effects of the drug with some cell lines responding to doses of less than 100nM, 
while in others doses of over 10μM are needed to induce a response (94, 114). KRAS 
and BRAF mutational status is thought to be an indicator of sensitivity to AZD6244. 
Data reported by Davies et al (94) demonstrated that cells carrying KRAS or BRAF 
mutations are more sensitive to the drug, presenting more growth inhibition in 
response to treatment than those with wild type genes. However, Balmanno et al 
(114) have demonstrated that neither KRAS or BRAF mutational status nor the degree 
of p-ERK1/2 inhibition observed after exposure to the drug, are good indicators of 
sensitivity to AZD6244. In this study, groups of cells harbouring the same mutation 
included cells that displayed high sensitivity, but also resistance to the drug. 
Similarly, cells presenting the same degree of p-ERK1/2 decrease displayed opposite 
outcomes in terms of growth inhibition, and caspase-dependent apoptosis occurred 
after 18h of treatment in sensitive cell lines, while in resistant cell lines this was not 
observed even after 72h. 
 
While cell line studies are a good starting point for identifying markers of 
sensitivity, these do not recapitulate the complex signalling pathways and cell 
heterogeneity found in human tumours. Treatment of tumours growing in an ex vivo 
model is an ideal way to identify markers of sensitivity / resistance to this agent in a 
more realistic setting. My previous data suggested that regardless of growth 
conditions, tumours undergo extensive apoptosis within 24h of being placed in 
culture. Therefore, I set out to establish if response to AZD6244 could be measured 
using acute (short time point) treatments. I wished to use this method to determine 
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patient tumours sensitivity to AZD6244, and to identify markers of sensitivity / 
resistance that are more relevant to the clinic. 
 
Results: 
4.1 – MEK1/2 inhibition can be measured within 1h of treatment with 
AZD6244 in colorectal cancer cell lines 
Markers of resistance / sensitivity to AZD6244 have been previously 
proposed in studies developed with colorectal cancer cell lines. However, the 
relevance of these data to human tumours is currently unknown. 
I first used a panel of colorectal cancer cell lines in order to establish the 
minimum time point at which effects of AZD6244 could be measured. Based on data 
reported in the literature, I selected the colorectal cancer cells lines HRT18, HCT116 
and RKO as these vary in their KRAS and BRAF mutational status and their reported 
sensitivity to AZD6244. RKO (BRAF mutant) and HRT18 (KRAS mutant) are 
intrinsically resistant to MEK1/2 inhibition by AZD6244 while HCT116 cells (KRAS 
mutant) are more sensitive (114). The concentrations of AZD6244 utilised were 
based on those that are clinically relevant.  
Colorectal cancer cells were treated with 0, 0.1 or 3µM AZD6244 for 1, 3 
and 6h then western blot analysis was used to examine effects on the ERK1/2 
pathway. These data indicated that even at these relatively low concentrations, the 
agent inhibited ERK1/2 phosphorylation within 1h of treatment. For RKO and 
HRT18 cells, this effect was most apparent at the 3µM concentration. However, for 
the more sensitive HCT116 cells, 0.1µM of the agent was sufficient to completely 






















Figure 4.1: Response to AZD6244 treatment can be measured with acute 
(short) time points in colon cancer cell lines. Figure shows western blot 
analysis of p-ERK1/2 in a panel of cell lines. Inhibition of ERK1/2 
phosphorylation is measurable after 1h of treatment with AZD6244 and its 
dose-dependent, especially in RKO and HRT18 cells. Native ERK1/2 levels 
are shown. β-actin was used as a loading control. 
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Interestingly, AZD6244 did not appear to inhibit p-ERK1/2 activity at the longer 
time points in HRT18 cells. This might be indicative of the feedback mechanisms 
described by Little et al (92) (see Introduction).  
To further investigate whether sensitivity to AZD6244 can be measured using 
short term treatment with the agent, I next analysed the effects of the above treatment 
regime on cell proliferation and apoptosis. I found that within this time scale, the 
drug had a minimal effect on cell proliferation in all three cell lines tested, as 
indicated by immunocytochemistry for Ki-67 expression (data not shown). I also 
found that the agent had a minimal effect on apoptosis in HRT18 cells and RKO cells 
(Figure 4.2). However, dose-dependent induction of apoptosis was observed in the 
more sensitive HCT116 cells 1h after exposure to 0.1 and 3µM of the agent (Figure 
4.2).   
These data indicate that MEK inhibition by AZD6244 can be robustly 
measured after only 1h of treatment with either 0.1 or 3µM of drug, depending on 
sensitivity to the agent. It also shows that more sensitive colorectal cancer cell lines 
show growth inhibition effects at acute time points. These data suggested that 
differential sensitivity to AZD6244 may be identified using acute treatments with 
clinically relevant doses of the agent.  
Based on the shortfalls of long term growth of tumours in culture and my 
findings with colorectal cancer cell lines, I proceeded to treat fresh colorectal tumour 
explants with AZD6244 in short term experiments. With these studies I aimed to: 
first, determine if acute treatments with AZD6244 can be used to identify sensitive 







Figure 4.2: Induction of apoptosis can be detected after 1h treatment 
with AZD6244 in sensitive colon cancer cell lines. Immunocytochemistry 
with antibodies for active caspase-3 was performed to investigate the effects 
of AZD6244 on apoptosis. Ten fields of view were captured per sample per 
treatment then the percentage of positive cells quantified. Graphs show the 
average of 3 experiments +/- SE. One tail Student’s t test was used to 
calculate p values. An asterisk (*) above the data point indicates p≤0.05. A 2-
fold increase in apoptosis was observed in HCT116 cells (bottom) after 1h of 
treatment with this agent. In RKO cells AZD6244 had minimal effects on 
apoptotic rates (top). Image at the bottom shows an example of an apoptotic 




4.2 – Establishment of a minimum time point at which AZD6244 effects 
can be measured in patient tumours  
 The protocol used in this study is outlined in Figure 4.3. Briefly, colorectal 
tumours samples collected at the time of resection were dissected into the relevant 
number of fragments, each of 1-2mm
2 
in size. Each fragment was immersed in 
supplemented MEM media containing 0, 0.1 or 3µM AZD6244, and incubated at 
37ºC with 95% CO2. All samples had a DMSO concentration of 0.03%. A proportion 
of the tumour was retained for a T0 control. Two wells were set up for each 
treatment condition at each time point so that one piece could be frozen for protein 
extraction, and one piece fixed and embedded for immunohistochemical analysis. I 
was unable to routinely set up duplicate wells for each assay type due to the 
extremely small nature of the tumours.  
The first three tumours were treated for 1, 3 and 6hrs. Using western blot 
analysis, I found that AZD6244 inhibited ERK1/2 phosphorylation in a dose-
dependent manner. Furthermore, for all samples, this inhibition was evident within 
1hr of treatment and showed no further decrease after 3 or 6hrs (Figure 4.4). Based 
on these data, and the fact that tumour samples were limited in size, I proceeded to 
treat tumours with 0, 0.1 or 3µM AZD6244 for 1h only.  
In total, 23 patient tumours were treated using this method. The group of patients 
included 15 males and 8 females diagnosed with colorectal cancer between the ages 
of 39 and 80, with 78% of the patients being diagnosed between the ages of 55 and 
80. Classification according to Duke’s staging system revealed that one tumour was 
stage A, five were stage B and ten were classified as stage C. Pathology information 












Figure 4.3: Schematic representation of the method. Tumours collected at 
the time of resection were immediately transferred to the lab, dissected and 
immersed in culturing media containing 0, 0.1 and 3μM AZD6244. Samples 
were harvested after 1-6h incubation and immediately frozen for protein 
expression, or fixed for immunohistochemical analysis. 
Figure 4.4: Inhibition of ERK1/2 phosphorylation in patient samples 
within 1-6h of treatment with AZD6244. Tumour explants were treated with 
AZD6244 for 1-6h and western blot analysis was performed on whole cell 
lysates with antibodies to native and phosphorylated ERK1/2. β-actin was 
used as a loading control. Data shows that inhibition of p-ERK1/2 is not time 




4.3 – Acute treatment with AZD6244 is sufficient to induce a 
pharmacodynamic response in human colorectal tumour explants 
 Studies developed in cancer cell lines and xenografts, and data from clinical 
trials show that treatment with AZD6244 rapidly inhibits ERK1/2 phosphorylation 
(115, 219). Therefore, my first approach was to determine if p-ERK1/2 was inhibited 
in tumours treated with AZD6244 for 1h. I extracted protein from tumour samples 
frozen immediately after harvest and performed western blot analysis with antibodies 
for phosphorylated and native ERK1/2. Blots were quantified using ImageJ software. 
Native and phosphorylated ERK1/2 intensities were normalised using β-actin to 
correct for variability in protein loading. Phosphorylated ERK1/2 intensity was then 
normalised for total (native) ERK1/2. 
Results show that AZD6244 inhibited ERK1/2 phosphorylation in all samples 
after 1h of treatment (Figure 4.5), and that in 21 samples treated with the agent, p-

































Figure 4.5: p-ERK1/2 inhibition in patient tumours treated with AZD6244. 
Tumours were treated with 0, 0.1 and 3μM AZD6244 for 1h and western blot 
analysis was performed on whole cell lysates with antibodies to native and 
phosphorylated ERK1/2. β-actin was used as a loading control. ImageJ was 
used to quantify blot intensities. Native and phosphorylated ERK1/2 levels were 
normalised with β-actin, and p-ERK1/2 was normalised with native protein. 
Western blots are shown on the right and respective quantification data are 
shown in graphs on the left. 
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Having demonstrated that this model was sufficient to detect p-ERK1/2 
inhibition, I next wished to determine if this pharmacodynamic response translated 
into inhibition of proliferation and/or induction of apoptosis. Tumour samples were 
fixed immediately after harvest, embedded, then consecutive 4μm sections were used 
for immunohistochemical analysis for proliferation marker Ki-67 and apoptosis 
marker active caspase-3. Expression of these markers was analysed in T0 and all 
cultured samples. By comparing the T0 sample with the non treated control I was 
able to assess maintenance of tissue integrity in culture. To evaluate drug response, I 
compared samples treated with 0.1μM and 3μM AZD6244 with non treated (0μM) 
controls. I performed quantitative image analysis on 5 fields of view per marker per 
sample, captured at 1000x magnification. Imaging was done in a “blind” fashion to 
remove bias (see Materials and Methods). For each marker, the percentage of 
positive cells per field was counted then the average of the five fields determined. An 
example of these data, for one patient, is given in Figure 4.6. The full data set for all 
patients is presented in Figure 4.7. I found that for all samples and for both markers, 
the percentage of positive cells was consistent between the five fields of view (see 

















Figure 4.6: Quantitative image analysis of proliferation and apoptosis 
markers. Tumours were treated with 0-3μM AZD6244 for 1h and 
immunohistochemistry was performed with antibodies to proliferation marker 
Ki-67 and apoptosis marker active caspase-3. Five fields of view per sample 
per treatment were captured at 1000x magnification, and the number of 
positive cell quantified. Graphs show average of 5 fields of view +/- SE. One 
tail Student’s t test was used to determine p values. Images and graphs show 



























Figure 4.7: AZD6244 effects on proliferation and apoptosis in all tumours 
treated. Tumours were treated with 0-3μM AZD6244 for 1h and effects on 
proliferation and apoptosis were measured using immunohistochemical 
analysis performed as described in Figure 4.6. Data is the average of 5 fields 
of view +/- SE in each tumour. Different patterns of response to AZD6244 are 




4.4 - Acute treatment with AZD6244 is sufficient to induce a phenotypic 
response in human colorectal tumour explants 
Analysis of the immunohistochemistry data revealed distinct patterns of 
response to AZD6244 in colorectal tumours (Table 4.1). Some samples demonstrated 
a clear dose response for both markers while others showed no response in either 
marker (Figure 4.7). Using the following criteria, I attempted to stratify the 
sensitivity of the samples to the agent:   
 Tumours that showed a dose-dependent decrease in proliferation and 
increase in apoptosis, and this change reached 2-fold (+/-20%) for both 
markers were classified as responders.  
 Tumours that presented a response in one marker at both doses or 2 
markers only at the lower dose were classified as intermediate responders.  
 Tumours that presented no change or an increase in proliferation and 
decrease in apoptosis were classified as non responders.  
 
According to these criteria, a sample was only classified as a responder if a 
response was observed in two separate pieces of tissue (wells). This minimised the 
possibility that the difference in levels of proliferation/apoptosis were a result of inter 
well variability between tumour pieces. The fact that a response was required in both 
markers also strengthened the data. For tumours where a response was only observed 
at the lower dose (intermediate responders) it cannot be ruled out that this response 














Table 4.1: AZD6244 effect on tumour proliferation and apoptosis. Table 
shows the levels of proliferation marker Ki-67 and apoptosis marker active 
caspase-3 in patients tumours treated with 0, 0.1 and 3μM AZD6244 for 1h, 
obtained by immunohistochemical analysis. Colour scheme represents the 
changes observed in the levels of these markers: Green indicates a >2-fold 
decrease in proliferation or increase in apoptosis; Yellow indicates a 2-fold (+/-
20%) variation in the levels of Ki-67 and active caspase-3; and Red indicates 
that no changes or an increase in proliferation and decrease in apoptosis were 
observed in these tumours. 
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Using these criteria I found that 6 samples showed an acute phenotypic 
response to AZD6244, ten tumours presented an intermediate response, and seven 
tumours did not respond to treatment with this agent (see Table 4.1 and Figure 4.8).  
When the data for patients in each of these groups were combined, clear 
patterns of response to the agent emerged (Figure 4.9). For the responding group 
there was a dose-dependent decrease in proliferation which reached significance for 
both doses (p=0.04 for 0.1μM and 0.003 for 3μM). There was also a dose-dependent 
increase in apoptosis which reached significance at the 3μM dose (p=0.02). For the 
intermediate group there was a significant decrease in proliferation (p=0.0007) and 
increase in apoptosis (p=0.001) at the 0.1μM dose. P values were calculated using 
one tail Student’s t test. However, minimal response was observed at the 3μM dose. 
For the non-responders there was no significant change in proliferation / apoptosis. 
 
Due the small nature of the tumours, I could not routinely set up replicates for 
the treatments. One tumour that I did treat in triplicate showed poor correlation 
between the replicates (Figure 4.10). However, this tumour was much larger in size 
(>10x) when compared to the other tumours which could potentially result in 
morphologic and homeostatic differences between the tumour pieces treated. These 
data highlight the importance of tumour heterogeneity, suggesting that different areas 
of the same tumour present differential sensitivity to AZD6244. Given that the 
combined data of all replicates is not representative of individual response, this 
























Figure 4.8: Tumour distribution based on sensitivity to AZD6244. 
Graph shows the number of samples in each response category 














Figure 4.9: Pattern of AZD6244-induced changes in proliferation and 
apoptosis in each response group. Tumours were treated with 0, 0.1 and 
3μM AZD6244, and effects on proliferation and apoptosis were evaluated using 
immunohistochemical analysis. Quantification of levels of expression of each 
marker in each individual tumour were performed as described in Figure 4.6. 
Graphs show the average levels of proliferation marker Ki-67 and apoptosis 
marker active caspase-3 in each response group. Data were pooled from all 
tumours of the same response group (Responders, n=6, +/- SE; Intermediate, 
n=10, +/-SE; Non responders, n=6, +/-SE). One tail Student’s t test was used to 










Figure 4.10: AZD6244 effects on proliferation and apoptosis in a patient 
tumour treated in triplicate. A single tumour was divided into multiple 
fragments and treated in triplicate. Immunohistochemistry was used to 
determine AZD6244 effects on proliferation and apoptosis as described in 
Figure 4.6. Top graphs show data obtained with each individual set of 
samples. Data shows inconsistent results between the replicates though they 
all present intermediate response to AZD6244. However, pooled data from the 
3 sets of treatments shown in the bottom graphs shows a response pattern 
characteristic of the non responsive group. One tail Student’s t test was used 
to determine p values. 
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Analysis of the above data revealed that there was considerable variability in 
the initial rates of proliferation and apoptosis between tumours (T0 samples). There 
was also variability in the maintenance of sample integrity when placed in culture 
(comparing T0 samples to 0μM controls). Therefore, I hypothesised that this 
variability might account for differences in response to treatment. However, when I 
compared the expression of Ki-67 and active caspase-3 at T0 in the three groups I 
found that there was no association between initial rates of proliferation and/or 
apoptosis and tumour response. Similarly, I found that there was no association 
between maintenance of tissue viability in culture and response to AZD6244 (Figure 
4.11a/b). This excludes any bias introduced by the culturing system.  
Taken together, these data suggest that acute treatments with AZD6244 can 



























































































































































































































































































































































































































































































































































































































































































































































































































































































4.5 - Inhibition of ERK1/2 phosphorylation cannot be correlated with 
phenotypic response 
 Previous reports indicated that a phenotypic response to AZD6244 correlates 
with levels of p-ERK1/2 inhibition in xenograft models (94) . Therefore, I next 
compared AZD6244 effects on tumour levels of Ki-67 and active caspase-3 with 
effects on p-ERK1/2. AZD6244-induced changes in levels of proliferation and 
apoptosis previously determined (see section 4.4) were compared with p-ERK1/2 
inhibition to ascertain if there is a correlation between pharmacodynamic effects and 
phenotypic response. Correlation coefficients were calculated between normalised 
expression values of p-ERK1/2 and Ki-67, and p-ERK1/2 and active caspase-3. 
As may be expected, given that in the responding group, all markers change 
in response to AZD6244, a strong positive correlation was observed between effects 
on p-ERK1/2 and Ki-67 in all six samples, and a negative correlation was observed 
between effects on p-ERK1/2 and apoptosis in 5 samples. However we also found 
that p-ERK1/2 decreased to the same extent in samples classified as intermediate and 
non-responders. This would suggest that the levels of p-ERK inhibition cannot 








































































































































































































































































































































































































































































































































































































4.6 – Further characterisation of patient tumour response to AZD6244 
To further characterise the patient tumour response to treatment with 
AZD6244 I also investigated the levels of other molecules known to be involved in 
the response to this agent. 
In addition to p-ERK1/2 inhibition, increased p21 and decreased cyclinD1 
levels have been associated with response to AZD6244 (95, 114). I analysed the 
expression of these markers in the first thirteen tumour explants treated. From this 
panel of samples, five tumours showed increased p21 expression in response to the 
agent (Figure 4.12a). However, this did not appear to be related with response as it 
was apparent in tumours classified as responders and non responders to treatment. I 
therefore proceeded to investigate expression of p27, a cell cycle control protein 
known to inhibit Cyclin D1/CDK4 and cause G1 phase cell cycle arrest (220) that 
has also been associated with response to AZD6244 treatment (95). I used western 
blot analysis to investigate levels of p27 in 9 of the above colorectal tumour samples. 
This panel included 2 tumours classified as responders, 5 tumours showing 
intermediate response, and 2 non responders. I found that p27 expression was only 
increased in 3 tumours treated with 0.1μM AZD6244 (116T, 117T and 118T). 
Therefore, I was unable to identify a pattern of expression of p27 related to tumour 
response to AZD6244 (Figure 4.12b).  
Cyclin D1 expression was also evaluated in the initial panel of thirteen 
tumours but the expected decrease was not observed in any sample (data not shown). 
In some samples, Cyclin D1 signal was very weak, even at T0, making it difficult to 











Figure 4.12: AZD6244 causes cell cycle arrest in patient tumours. Figure 
shows western blot analysis of p21 levels (A) in one tumour treated with 
AZD6244 for 1h, and p27 levels (B) in three tumours treated with the same 
regime. Increased p21 and p27 levels in treated samples suggests induction 
of cell cycle arrest in response to AZD6244. 
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I then looked at the expression of CDK4 in the remaining ten tumour samples but 
again AZD6244 effects on this marker could not be measured due to weakness of 
western blot signal observed in the majority of the samples.  
 These data suggests that patterns of response to AZD6244 shown in cell lines 
might not translate to patient tumours where a more complex network of events 
seems to be involved in the response to treatment with this agent.  
 
4.7 – Response to aspirin can be measured with acute treatments 
 Having shown that acute treatment of human tumour explants can be used to 
study the response to AZD6244, I hypothesised that this model is also useful to study 
the response to other therapeutic agents.  
 Work in the host lab has been aimed at understanding the mechanisms by 
which aspirin and related agents act against colon cancer cells. However, these 
studies have mainly been performed in colorectal cancer cell lines and xenografts, 
and the significance to human tumours has not yet been established. In these models, 
aspirin was shown to induce activation of the NFκB pathway, repression of NF- B-
driven transcription and consequently, the induction of apoptosis (134, 221). In this 
setting, aspirin was also reported to induce Cyclin D1 degradation and cell cycle 
arrest upstream of effects on NF- B (135). In more recent studies, the lab has 
demonstrated that an early response to aspirin is modulation of nucleolar structure 
and function. In particular, they have demonstrated that aspirin causes a decrease in 
levels of the critical component of the PolI transcription machinery, TIF-1A. 
Furthermore, this decrease happens as a very early response to the agent. 
138 
 
Given the novelty of this new data, I set out to determine whether the effects 
observed in colorectal cancer cells could be detected using acute treatment of human 
colorectal tumour explants. I treated 8 tumour samples with 0 and 100μM aspirin 
(which is the expected serum salicylate level after taking one 300mg tablet) and 
performed western blot analysis, to investigate levels of Cyclin D1, CDK4 and TIF-
1A. Immunohistochemical analysis was also performed on fixed tissue to investigate 
the effects of this agent on proliferation and apoptosis.  
I found that levels of both Cyclin D1 and CDK4 were very low, even in non 
treated controls (0μM), and that aspirin had minimal effect on the expression of 
either marker (data not shown). In contrast, I found that in 5/7 patient tumours 
analysed, aspirin caused a significant decrease in levels of TIF-1A, in keeping with 
data obtained from colorectal cancer cells (Figure 4.13). 
Quantitative analysis of tissue sections stained for Ki-67 and active caspase-3 
was carried out on 5 fields of view as described in section 4.3. I found that aspirin 
effects on proliferation and apoptosis were minimal, and variable between tumours 




















Figure 4.13: Aspirin reduces TIF1A levels in patient tumours. Figure shows 
western blot analysis of the levels of TIF1A in tumours treated with 0 and 
100μM aspirin for 1h. ImageJ was used to quantify blot intensities. TIF1A levels 
were normalised with β-Actin used as loading control. Data shows that TIF1A 
levels were reduced in 5/7 tumours as a result of aspirin treatment. Western 














Figure 4.14: Aspirin effects on tumour proliferation and apoptosis. Seven 
tumours were treated with 0 and 100μM aspirin for 1h. Effects on proliferation 
and apoptosis were measured by immunohistochemical analysis with 
antibodies for Ki-67 and active caspase-3. Five fields of view per sample per 
marker were captured, then the number of positive cells counted and the 
average between the 5 fields calculated. Data are the average of 7 tumours +/-
SE. One tail Student’s t test was used to calculate p values. Asterisk (*) 
indicates p≤5. Graphs show that aspirin effects on proliferation and apoptosis 
are not consistent between tumours, and a pattern of phenotypic response to 




 The data here presented demonstrate that by using a short term treatment 
regime, tumours showing hypersensitivity to the MEK1/2 inhibitor AZD6244 can be 
identified. The percentage of tumours found to be sensitive (27%) was similar to that 
observed by Adjei et al (115) who, in clinical studies, also observed a more than 2-
fold inhibition of proliferation in 25% of solid tumours from patients recruited for 
clinical trial. This suggests that this model can provide an indication of tumour 
sensitivity to AZD6244 and that it could therefore be used to identify patients more 
likely to respond to treatment with this agent. 
 Balmanno et al (114) have previously demonstrated that sensitivity to 
AZD6244 does not correlate with p-ERK1/2 inhibition, in colon cancer cell lines. In 
fact, I found that p-ERK1/2 was inhibited in all tumours within 1h of treatment with 
AZD6244 regardless of phenotypic response. These data are also in keeping with that 
of Adjei et al (115) who found that despite full inhibition of ERK1/2 phosphorylation 
within one hour of treatment, effects on tumour proliferation were only observed in a 
subset of patients; and that of Davies et al (94) who reported similar observations 
with mouse xenografts.  
 In order to analyse the data, I established a system to categorise the tumours 
into responders and non responders. To be categorised as a responder, tumours were 
required to show a more than 2-fold (+/- 10%) increase in apoptosis and decrease in 
proliferation at both 0.1 and 3μM AZD6244. As this involved response in two 
separate pieces of the tumour, this categorisation contributed to remove the potential 
that the differences in levels of proliferation / apoptosis were due to tumour 
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heterogeneity. However, it excluded tumours that only responded at a lower dose, 
which may be a very important group (see Chapter 5).  
From the group of non responder tumours, those that showed a lack of 
AZD6244-induced effect on proliferation and apoptosis, some presented increased 
p21 levels after 1h treatment with the agent. One possibility is that some non 
responder tumours quickly underwent cell cycle arrest, but have not been exposed to 
the agent long enough for apoptotic response to be induced. This was previously 
reported by Balmanno et al (114) in HCT116 cells in which cell cycle arrest was 
observed shortly after exposure to AZD6244, but effects on apoptosis could only be 
measured after 18h of treatment. However, conclusions could not be drawn based on 
p21 levels only as, in some cells lack of expression of this marker is associated with 
homozygous p53 mutation (222). Therefore, the lack of p21 increase in some of the 
tumours analysed cannot be related to drug response without determining p53 status. 
Using this treatment regime, I was restricted to examining tumour response to 
AZD6244 within one hour of treatment. However, Davies et al (94) reported 
AZD6244-induced apoptosis 8 h after treatment in mouse xenografts; and Balmanno 
et al (114) reported this effect after 18h of treatment in more sensitive cells, and lack 
of effect on apoptosis in resistant cell lines even after 72h of exposure to the drug. 
This would suggest that the tumours I identified as responders presented 
hypersensitivity to AZD6244.  
My findings showing that HCT116 cells have increased sensitivity to 
AZD6244 are in keeping with those of Davies et al and Balmanno et al (94, 114). 
Importantly, I found that AZD6244 induced apoptosis in HCT116 cells within 1h of 
treatment. Though such an early apoptotic response has not been observed by other 
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authors, it provided good indication that a phenotypic response to AZD6244 could be 
detected using acute (short time point) treatment of patient tumours. Data obtained 
with HRT18 and RKO cells are also in keeping with that of Balmanno et al (114) 
regarding intrinsic resistance to AZD6244 and lack of caspase mediated apoptosis. 
However, a wide range of sensitivities to AZD6244 has been previously observed in 
colon cancer cell lines. 
Data obtained with aspirin also indicates that the acute treatment model might 
be useful for testing therapeutic response to any agents that rapidly induce a 
pharmacodynamic response. It was very interesting to find that patient tumours show 
TIF1A depletion in response to aspirin. I also found that this is not associated with 
changes in proliferation or apoptosis. However, this is not surprising as in tissue 
culture systems, changes to TIF1A are observed within 1h of treatment whereas the 
indication of apoptosis, at the same aspirin dose, is not observed until 16h after 
treatment. Given that TIF1A is critical for ribosomal biogenesis (223), and depletion 
of this protein has previously been shown to mediate apoptosis (224), aspirin effects 
on TIF1A will undoubtedly contribute to the pro-apoptotic / anti-tumourigenic 
effects of this agent. Further studies are currently underway in the lab to identify 
markers for TIF1A response. 
In conclusion, I have identified a method of categorising colorectal cancer 
response to AZD6244 and potentially aspirin. I have also identified tumours that can 
































AZD6244 has been extensively studied in cell lines and tumour xenografts 
models, and in clinical trials, but even though the response to this therapeutic agent 
has been significantly characterised, markers of sensitivity and resistance have not 
yet been fully established. Markers of resistance to AZD6244 such as the presence of 
KRAS or BRAF mutations, activation of the Akt pathway or increased levels of basal 
Cyclin D1 have been proposed (94, 114). However, the significance of these markers 
to the clinic is still unknown.  
 My data obtained with patient tumours treated with AZD6244 revealed 
distinct patterns of response to this agent. Therefore, I set out to investigate if each of 
the response groups presented distinct molecular signatures that would allow for 
identification of markers of sensitivity/resistance to AZD6244 in a more clinically 
relevant context. 
The presence of KRAS or BRAF mutations is a common feature of cancers of 
different origins. The presence of these mutations leads to a constitutively active 
MAPK pathway which results in increased expression of genes responsible for 
tumour proliferation and survival. In colorectal cancer, these mutations occur in 45% 
and 12 % of tumours, respectively, and are mutually exclusive (98, 100). KRAS 
mutations occur predominantly in codons 12 and 13, and less frequently in codons 
61, 63 and 146. In colorectal cancers the frequency of these mutations is ~80% and 
18% for codons 12 and 13 respectively; and less than 5% for codons 61, 63 and 146 
(225, 226). The most frequent BRAF mutation occurs in exon 15: T1796A by 
substitution of valine by glutamic acid at position 599, and it’s commonly known as 
V600E mutation (227, 228). Given that these mutations lead to hyperactivity of the 
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ERK1/2 pathway, it has been proposed that tumours harbouring either mutation 
would present increased sensitivity to MEK1/2 inhibition by AZD6244. I therefore 
proceeded to evaluate the mutational status of KRAS and BRAF in my panel of 
tumours and compare it with pharmacodynamic and phenotypic response to 
treatment with this agent. Tumours were also tested for PIK3CA mutations as the 
activation of this pathway is known to increase resistance to MEK1/2 inhibition (229, 
230). PIK3CA encodes the p110 catalytic subunit of PI3K, and mutations in this gene 
lead to elevated Akt activity (231, 232). A recently published study performed on the 
largest European cohort of metastatic colorectal cancers identified PIK3CA 
mutations in 14.5% of patients (233).  
I also investigated the correlation between phenotypic response to treatment 
with AZD6244 and levels of markers thought to be involved in the response to this 
agent such as Cyclin D1 and Akt. Using Reverse Phase Protein Arrays (RPPA). I 




5.1 - Analysis of KRAS, BRAF and PIK3CA mutational status 
To determine mutational status of KRAS and BRAF in my panel of tumours, 
I initially used Applied Biosystem’s BigDye Terminator v.3.1 Cycle Sequencing 
protocol to sequence PCR products previously generated using primers for all KRAS 
mutations and BRAF
V600E
 mutation. However, after several attempts I concluded that 
this method was not sensitive enough to detect mutations in samples with high 
cellular heterogeneity. Mutational analysis was then performed by AstraZeneca. 
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Using their Roche Cobas system KRAS mutations located in codons 12 or 13, 
BRAF
V600E
 mutation, and PIK3CA mutation, were investigated.  
 
5.1.1 - AZD6244 induces p-ERK1/2 inhibition in mutant and wild type 
tumours 
 From my panel of samples, 27% of tumours were found to be KRAS mutant, 
8% BRAF mutant and 8% carried PIK3CA mutations, including one tumour where a 
BRAF mutation was also found.  
First, I compared the levels of p-ERK1/2 observed at T0 between wild type, 
and KRAS or BRAF mutant tumours. I found that, contrary to what was expected, 
mutant tumours did not show higher levels of p-ERK1/2 activity at T0 compared to 
their wild type counterparts (Figure 5.1). There was also no difference in response to 
AZD6244 between wild type and mutant tumours, which is consistent with the 
mutational status not affecting basal p-ERK1/2 levels (Figure 5.2). Similar results 
were obtained with PIK3CA mutant tumours in that there was no correlation 
observed between mutational status, basal levels of p-ERK1/2 or the effects on 






















Figure 5.1: Patient tumours carrying KRAS or BRAF mutations do not 
present increased ERK1/2 activity. Western blot analysis was performed 
on whole cell lysates extracted from T0 samples with antibodies to native 
and phosphorylated ERK1/2. β-actin was used as a loading control. ImageJ 
was used to quantify blot intensities. Native and phosphorylated ERK1/2 
levels were normalised with β-actin, and p-ERK1/2 was normalised with 
native ERK1/2 protein. Graph shows the expression of p-ERK1/2 at T0 in 
wild type and KRAS, BRAF and PIK3CA mutant tumours. Contrary to what 
was expected, tumours carrying KRAS or BRAF mutations did not show 
increased p-ERK1/2 activity when compared to wild type tumours. 
Figure 5.2: KRAS, BRAF and PIK3CA mutational status does not 
influence AZD6244-induced p-ERK1/2 inhibition. Tumours were treated 
with 0, 0.1 and 3μM AZD6244 for 1h and western blot analysis was performed 
as described in Figure 5.1 to investigate effects of this agent on p-ERK1/2 




5.1.2 - KRAS and BRAF mutational status is not sufficient to predict 
phenotypic response to treatment with AZD6244 
Next, I compared the mutational status of 21 tumours with proliferative / 
apoptotic response to AZD6244. I found that only two tumours with KRAS or BRAF 
mutations showed a dose-dependent inhibition of proliferation (as determined by 
immunohistochemistry with antibodies to Ki-67 (see section 4.3) (Figure 5.3). 
Induction of apoptosis was also observed in tumours with mutations in these genes, 
but was not dose-dependent (Figure 5.4). Therefore, KRAS and BRAF mutant 
tumours cannot be classified as responders according to the previously established 
response criteria (See section 4.3 and Figure 5.5). These data would suggest that the 
mutational status of these proteins alone cannot be used as an indicator of phenotypic 
response to AZD6244 in this explant model.  
As mutational status may confer increased sensitivity to the drug, I next 
focussed on the phenotypic response to the lower dose of the agent (0.1uM). 
Interestingly, I found that all tumours (7/7) carrying these mutations presented 
inhibition of proliferation in response to low dose treatment with AZD6244, and that 
in 4 out of 7 tumours this effect was more than 2-fold (Figure 5.6). This is in contrast 
to wild type tumours where only 7/13 samples showed inhibition of proliferation in 
response to 0.1μM AZD6244, and from these 7 only 3 displayed a more than 2-fold 
effect (Figure 5.6). When I looked at the effects of 0.1μM AZD6244 on apoptosis in 
wild type and mutant tumours I found that response to low dose AZD6244 seemed to 
be more variable across wild type tumours. However, no further conclusions could 












Figure 5.3: AZD6244 effects on proliferation in wild type and KRAS, 
BRAF and PIK3CA mutant tumours. Tumours were treated with 0, 0.1 and 
3μM AZD6244 and effects on proliferation were measured by 
immunohistochemical analysis with antibodies to proliferation marker Ki-67. 
Five fields of view were captured per sample and the number of positive cells 
was counted. Data are the average of 5 fields of view +/- SE. One tail 
Student’s t test was used to calculate p values. Only values of p≤5 are shown. 
Data suggests that KRAS and BRAF mutant tumours are more sensitive to 
treatment with 0.1µM AZD6244 than wild type tumours. 4 in 7 mutant tumours 
showed significant inhibition of proliferation at this concentration, while this 
was only observed in 2 in 13 wild type tumours. However, this effect was not 














Figure 5.4: AZD6244 effects on apoptosis in wild type and KRAS, BRAF 
and PIK3CA mutant tumours. Tumours were treated with 0, 0.1 and 3μM 
AZD6244 and effects on apoptosis were measured by immunohistochemical 
analysis with antibodies to apoptosis marker active caspase-3. Marker 
quantification was performed as described in Figure 5.3. Data are the average 
of 5 fields of view +/- SE. One tail Student’s t test was used to calculate p 
values. Only values of p≤5 are shown. No correlation was found between the 





















Figure 5.5: Tumour distribution based on sensitivity to AZD6244 and 
mutational status of KRAS, BRAF and PIK3CA. Figure shows that 
mutational status of KRAS, BRAF and PIK3K does not correlate with previously 














Figure 5.6: Effects of low doses of AZD6244 on proliferation in wild 
type and KRAS and BRAF mutant tumours. Immunohistochemical 
analysis of proliferation marker Ki-67 was performed on tumours treated with 
0 and 0.1µM AZD6244 as described in Figure 5.3. Data are the average of 5 
fields of view +/- SE. One tail Student’s t test was used to calculate p values. 
Only values of p≤5 are shown.  All mutant tumours present inhibition of 
proliferation in response to AZD6244 and in 4/5 tumours this effect has 
reached 2-fold. In wild type tumours the effects of this agent are variable 














Figure 5.7: Effects of low doses of AZD6244 on apoptosis in wild type and 
KRAS and BRAF mutant tumours. Immunohistochemical analysis of 
apoptosis marker active caspase-3 was performed on tumours treated with 0 
and 0.1µM AZD6244 as described in Figure 5.3. Data is the average of 5 fields 
of view +/- SE. One tail Student’s t test was used to calculate p values. Only 
values of p≤5 are shown.   The majority of mutant tumours show induction of 
apoptosis in response to AZD6244 though this effect did not reach 2-fold in any 
of the samples. In wild type tumours effect on apoptosis is variable, and only 3 
tumours show a 2-fold increase in apoptosis in response to this agent. 
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Surprisingly, in this model system the presence of PIK3CA mutation seems to 
increase sensitivity to treatment with AZD6244. Tumours carrying this mutation 
presented a dose-dependent inhibition in proliferation and induction of apoptosis 
(Figures 5.3 and 5.4). However, the number of samples with this mutation is too 
small to draw any firm conclusions. Interestingly, increased sensitivity to AZD6244 
was also observed in one tumour harbouring both BRAF and PIK3CA mutations, but 
again sample size is too small to establish a correlation between genotype and 
phenotypic effects.  
In conclusion, the above data would suggest that the presence of a mutation 
in BRAF or KRAS may predict a response to low dose AZD6244.   
 
5.2 - Other markers of response to treatment with AZD6244 
In addition to mutational status, other factors have been associated with 
sensitivity to AZD6244. For example, reports suggest that cells addicted to the 
MAPK pathway are more likely to respond to treatment with AZD6244 (234, 235). 
Therefore, I hypothesised that the level of ERK1/2 activation at T0 could be an 
indicator of the changes observed in proliferation and apoptosis in response to 
AZD6244. However, comparison of p-ERK1/2 levels between T0 samples showed 
significant variability in the levels of this marker in all of previously established 
response groups. Therefore, no direct association between levels of p-ERK1/2 























Figure 5.8: Basal ERK1/2 activity does not correlate with phenotypic 
response to AZD6244. Graph shows the expression of p-ERK1/2 at T0 
obtained by western blot analysis as described in Figure 5.1. All T0 samples 
were examined in parallel in a total of 2 gels. Expression of this marker is 
variable between tumours displaying the same phenotypic response pattern 
indicating that there is no association between the expression of p-ERK1/2 at 
T0 and response to AZD6244. One tail Student’s t test was used to calculate 
the p value between responders and non responders. p=0.04. 
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Balmanno et al previously suggested that high basal levels of p-Akt and 
Cyclin D1 can be indicators of resistance to AZD6244, in cell lines (114). Therefore, 
I analysed the expression of these markers at T0 in all tumour groups. Western blot 
analysis showed that there was no correlation between basal levels of Cyclin D1 and 
tumour response to AZD6244 (Figure 5.9). However, I did find that basal Akt 
activity was higher in the intermediate responding and non responding tumours 
(Figure 5.9). 
Taken together, these data indicate that markers of sensitivity currently 
identified in cell line and xenograft models are not reflected in this explant model of 
colorectal cancer. Using a candidate approach and Reverse Phase Protein Arrays I set 
out to evaluate the expression of a variety of molecular markers, in a subset of 
responding and non responding tumours, to determine the molecular differences 
























Figure 5.9: Basal activity of Akt and Cyclin D1 does not correlate with 
phenotypic response to AZD6244. Graph shows the expression of p-Akt and 
Cyclin D1 at T0 obtained by western blot analysis with antibodies for native and 
phosphorylated Akt, and Cyclin D1. β-Actin was used as loading control. 
Protein levels were normalised with β-actin, and phosphorylated Akt was 
normalised with native protein. All T0 samples were examined in parallel in a 
total of 2 gels. Data shows that Cyclin D1 levels are variable between tumours 
displaying the same phenotypic response pattern indicating there is no 
association between the levels of this protein at T0 and response to AZD6244. 
One tail Student’s t test was used to calculate the p value between responders 
and non responders. p=0.051. Interestingly, p-Akt levels seem to be increased 
in tumours classified as intermediate and non responders. One tail Student’s t 





5.5 – Reverse Phase Protein Analysis 
 Reverse phase protein arrays (RRPA) are an inexpensive, sensitive, high-
throughput, proteomic technology which allows parallel quantification of protein 
targets on multiple samples in an array-based format. Researchers at the IGMM have 
previously used this technique to quantify differential expression of active (e.g. 
phosphorylated) and parental proteins in human breast and ovary tissue in response 
to drug treatments. The high throughput of the method together with the fact that 
relatively small concentrations of proteins are required, make this assay ideal for 
analysis of my panel of tumours treated with AZD6244.  
For this assay, I used samples from three responding tumours and three non-
responding tumours as I believed this would be the most likely approach to reveal 
markers of resistance/response with the resources available. Protein lysates from 
these samples were spotted onto nitrocellulose coated glass slides. These slides were 
probed with antibodies to 39 selected proteins. For some of these proteins, antibodies 
to the native and the phosphorylated form were used, making a total of 64 antibodies.  
The proteins analysed included proteins involved in the maintenance of basic cellular 
functions like ubiquitination, cell cycle control, proliferation, signal transduction, 
DNA repair and stress response and apoptosis. See Table 5.1 for details.  
RPPA analysis was performed as an external service in the Edinburgh Cancer 
Research Centre. 
Three proteins (p-ERK1/2, p-Akt and Cyclin D1) that were analysed by 
RPPA had previously been analysed by western blot analysis. Therefore,  firstly I 
compared the expression of these proteins in T0 samples obtained by western blot 

























































































































































I found that p-ERK1/2 expression at T0 was remarkably similar between 
assays, and that there was good correlation between the p-Akt levels detected by 
western blot analysis and with the RPPA (Figure 5.10). However, some discrepancy 
between assays was observed in the expression of Cyclin D1. As I previously 
mentioned, the Cyclin D1 signal in western blot assays was very poor, and in fact, 
intensity achieved in the RPPA was much higher. This suggests that levels of Cyclin 
D1 obtained by RPPA analysis might be more accurate possibly due to the use of a 
serial protein dilutions or a better antibody (Figure 5.10). Next, I compared results 
obtained with RPPA and western blot analysis for AZD6244-mediated inhibition of 
p-ERK1/2. Again, I found that patterns of p-ERK1/2 inhibition obtained by western 
blot analysis strongly correlated with those obtained with the RPPA (Figure 5.11). 
These data were very encouraging as it supported the validity of my previous 
findings with p-ERK1/2, and supported the use of RPPA. However, when the rest of 
the RPPA data was analysed, I found that I could not relate any protein expression or 
phosphorylation status changes with response to AZD6244. A summary of these data 
























Figure 5.10: Western blot analysis data presents similarities with RPPA 
data. Western blot analysis was performed on whole cell lysates of two subsets 
of responding and non responding tumours, as described in Figures 5.1 and 
5.9. RPPA analysis was performed on the same lysates. Graphs show that 
good correlation between two assays was obtained for p-ERK1/2 and p-Akt 













Figure 5.11: Western blot and RPPA analysis of AZD6244-induced p-
ERK1/2 inhibition. Western blot analysis was performed on whole cell 
lysates of two subsets of responding and non responding tumours treated 
with 0-3μM AZD6244, as described in Figure 5.1. RPPM analysis was 
performed on the same cell lysates. Graphs show strong correlation 






















Table 5.2: Summary of RPPA results. Table shows the levels of an array of 
markers evaluated using RPPA analysis in a subset of responding and non 
responding tumours treated with 0, 0.1 and 3µM AZD6244 for 1h. 
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RPPA analysis also failed to provide an indication of the effects of AZD6244 
on proliferation and apoptosis, especially in responder tumours where a dramatic 
phenotypic effect was detected by immunohistochemical analysis. Levels of 
proliferation marker Ki-67 detected with this assay were very low, and therefore, 
could not be related with the levels previously obtained by immunohistochemical 
analysis.  In the RPPA, effects on apoptosis were evaluated using antibodies for pro-
caspase-3 while by immunohistochemistry it was the levels of active caspase-3 that 
were investigated. Therefore, I could not compare apoptotic response data obtained 
with the two assays. 
One of the limitations of this particular assay was the fact that a relatively 
small number of proteins involved in the MAPK pathway could be investigated, and 
only two ERK1/2 targets were analysed. The remaining proteins analysed are 
involved in more general cellular functions or are proteins typically activated in 
cancer, but that might not necessarily be affected by MEK1/2 inhibition with 
AZD6244.  
 
5.6 – Response to AZD6244 is not correlated with histopathological 
criteria 
 It is widely known that patients presenting tumours of the same Dukes or 
TNM stages present different outcomes and respond differently to the same 
therapeutic regimes. Therefore, I compared the histopathological data of the patients 
recruited for this study to determine if there is a correlation between the response to 
AZD6244 and tumour’s stage or other pathological properties. 
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 A summary of the histopathological data can be found in Table 5.3. I found 
that the tumour stage, either Dukes or TNM, distribution was similar in all response 
groups. Histological properties and tumour differentiation were also the same in all 
three groups. I then looked at the patient’s age at diagnosis and found that the 
spectrum of ages was very similar between response groups. These observations 
further contribute to the notion that response to therapy involves a variety of 
mechanisms that cannot be predicted based on tumour morphology only, and that 
comprehensive molecular characterisation of the disease as well as individual 

































































































































































































 The frequency of KRAS mutations reported in the literature is 40-50%. 
However, mutational rates vary slightly with geographic region (98, 236). Analysis 
of KRAS mutational status in my panel of tumours revealed that 27% were KRAS 
mutant. Interestingly, the same rate of KRAS mutations was found in patients 
admitted for surgery in Scotland, between 1997 and 1999 (237).  
Contrary to what was expected, tumours carrying KRAS or BRAF mutations 
did not present increased basal p-ERK1/2 activity when compared to wild type 
tumours. One possible explanation is the fact that pathway activation might have 
been affected during the period between tumour resection and arrival to the lab. As 
mutant tumours are thought to be addicted to this pathway, this effect would be more 
dramatic in these tumours then in wild type tumours, resulting in similar basal levels 
of p-ERK1/2 between samples. The concept of pathway addiction was demonstrated 
in cell lines (234, 235) bringing up the possibility that such observations result from 
factors inherent to the study model. In an in vivo environment where tumour cells are 
regulated by a variety of factors, pathway addiction and increased levels of p-
ERK1/2 might not occur. 
 I also found that the mutational status of KRAS and BRAF did not correlate 
with phenotypic response to 3μM AZD6244. Therefore, as I categorised responder 
tumours as those that responded at both doses (to remove potential variability in 
proliferation / apoptosis between tumour fragments) there appeared to be no 
correlation between KRAS and BRAF mutational status and phenotypic response. 
However, there seemed to be a correlation between the presence of these mutations 
and response to 0.1μM of this agent. These data may suggest that with 0.1μM 
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AZD6244 the response is more specific than with 3μM, or that at higher doses 
response observed might have resulted from the inactivation of short term feedback 
mechanisms that control pathway homeostasis and are regulated by p-ERK1/2 (see 
Introduction). Inhibition of p-ERK1/2 might have prevented feedback inactivation of 
KRAS or BRAF forcing these kinases to activate alternative effectors like PI3K or 
IKK, which in turn promote proliferation and inhibit apoptosis compensating for 
inactivation of the MAPK pathway. However, more work is needed to examine the 
correlation between KRAS and BRAF mutations and response to AZD6244. Data also 
suggests that wild type and mutant tumours present distinct mechanisms of response 
to the drug and that sensitivity to AZD6244 might vary with the dose of the agent. If 
that’s so, results supporting or denying the importance of these mutations as markers 
of response might have been influenced by the drug concentrations used by the 
authors.  
Analysis of other markers of response proposed in the literature (114) also 
revealed no correlation between the basal levels of p-Akt and Cyclin D1, and 
sensitivity to AZD6244 in this study model.  
 RPPA analysis of p-ERK1/2 and p-Akt levels showed strong correlation with 
previously performed western blots analysis of the same proteins. Good correlation 
between the two assays was also found for AZD6244-induced inhibition of p-
ERK1/2 in responder and non responder tumours. This indicated that RPPA’s are a 
reliable and robust method of analysis that could be used to detect variations in the 
levels of a variety of proteins, and establish a molecular signature of response to 
AZD6244. However, RPPA data revealed no correlation between the levels of other 
proteins analysed or phosphorylation status changes, and phenotypic response. One 
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of the shortfalls of the RPPA is that, due to the nature of the assay, antibodies require 
validation prior to use to assure that the expected sensitivity is achieved in every 
assay. Antibody validation is performed by comparing results obtained by RPPA and 
western blot analysis. However, due to low sensitivity of the assay, changes in some 
proteins cannot be detected by western blot analysis which limits the range of 
antibodies to be used in RPPA assays. For this reason the number of proteins that I 
was able to investigate was limited, and it included only a few proteins directly 
involved in the ERK1/2 pathway.  
 Higher throughput methods are needed to investigate a wider range of 
proteins and detect subtle molecular changes in response to AZD6244. In a recently 
published paper, Dry et al (238) revealed an 18-gene signature that allows for the 
measurement of MEK1/2 activity independently of genotype, using RT-qPCR 
assays. However, this signature was identified in cancer cell lines. Though it is 
fundamental to test the validity of this 18-gene signature in human colorectal 
tumours treated with AZD6244 this could not be performed with my panel of 
samples. The small size of the tumours limited the choice of analysis methods, and 
therefore RNA samples could not be obtained from the tumours. An alternative 
might be to extract RNA from fixed tissue.  
Taken together the data presented here indicate that even though acute 
treatment with AZD6244 can induce a strong phenotypic response in human 
colorectal tumours, the mechanisms behind it are still largely unknown due to the 
lack of correlation between tumour properties and sensitivity to the drug. Tumours 
with mutations in KRAS or BRAF did not present increased ERK1/2 activity as 
initially expected, and AZD6244-induced p-ERK1/2 inhibition was equivalent in 
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mutant and wild type tumours. This offers an explanation to why the mutational 
status of these proteins might not be an indicator of sensitivity to this agent. 
Expression of markers identified in cell lines also failed to correlate with tumour 
response to AZD6244 suggesting that tumour properties not found in cell lines, like 
the presence of stromal cells, extracellular matrix and tumour microenvironment, 
also have a role to play in therapeutic responses. Nevertheless, acute treatment of 
patient tumours with AZD6244 together with a higher throughput analysis system 
that allows for a more comprehensive overview of the changes occurring in response 
to treatment, and validation methods for the confirmation of the results obtained 
would make a powerful tool to identify markers of sensitivity that are more relevant 




































 AZD6244 has shown some promise in clinical trials. However, the best 
outcome reported so far is disease stabilisation. This agent effectively reduces 
tumour growth but it does not consistently reduce tumour size (115, 116). AZD6244 
has a cytostatic effect that seems to be enhanced when used in combination with 
agents that target pathways thought to be involved in the resistance to treatment with 
this drug. One such pathway is the PI3K pathway, which is activated by RAS (239) 
or by mutations in PI3K (229). Mutations in other proteins, such as Akt and PTEN, 
are also frequently found in a variety of solid tumours, and lead to constitutive 
activation of the PI3K pathway promoting growth, proliferation and survival (240). 
Combinations of AZD6244 with PI3K, Akt or mTOR inhibitors have been proposed 
for the treatment of cancers of different origins including colorectal tumours, and 
have so far shown promise in vitro and in vivo (119-121). Furthermore, AstraZeneca 
has recently announced a Phase I clinical trial to test combinations of AZD6244 and 
Akt inhibitor MK-2206 (241).  
Combinations of AZD6244 and currently used therapeutic agents have also 
been proposed. Clinical trials to assess the efficacy of AZD6244 and Capecitabine 
for the treatment of advanced pancreatic cancer are currently ongoing (242), and 
AZD6244 has also been shown to increase sensitivity to the chemotherapy agent 
docetaxel in melanoma cells (243). 
Work in the host lab has identified a novel mechanism by which aspirin acts 
against colorectal cancer cells (see section 4.7 in Chapter 4). Interestingly, upon 
analysis of this mechanism, I realised that many of the pathways known to cause 
resistance to AZD6244 are targeted by aspirin. For example, high basal levels of 
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Cyclin D1, p-ERK1/2 and p-Akt are associated with acquired resistance to AZD6244 
(114) while aspirin is known to induce degradation of Cyclin D1 (133) and de-
phosphorylation of ERK1/2 and Akt (244). Furthermore, aspirin can inhibit the 
mTOR pathway which will limit the effects of high p-AKT on cell proliferation and 
apoptosis (136). Overexpression of MEKK1 (RAF) has also been associated with 
resistance to AZD6244 and it has been suggested that the mechanism is through 
stimulation of IKK (IκB Kinase) and consequently, activation of NF- B’s anti-
apoptotic function (245, 246). Aspirin has previously been shown to inhibit NF- B 
signalling in colon cancer cells, which may allow tumours to overcome resistance to 
AZD6244 (133). Based on these data, I hypothesised that tumour sensitivity to 
AZD6244 could be enhanced in the presence of aspirin. However, the outcome of 
targeting both these pathways simultaneously has not yet been reported. Therefore, I 
set out to determine the combined effects of aspirin and AZD6244 on colorectal 
cancer cell growth and death. 
 
Results: 
6.1 AZD6244 and aspirin present synergistic effect in colorectal cancer 
cell lines 
 In order to test this hypothesis, I firstly used a panel of colorectal cancer cell 
lines and the Chou-Talalay median-effect method, which is the method most 
frequently described in the literature to investigate the effects of drug combinations 
on cell growth. This method, which was developed by Ting-Tao Chao and Paul 
Talalay in 1983, determines if drug combinations are synergistic, antagonistic or 
additive using relatively few measurements. It can be applied to both hyperbolic and 
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sigmoidal dose-response curves, regardless of whether the drugs act independently of 
each other or not (247). This method was used to determine whether aspirin and 
AZD6244 have a synergistic, antagonistic or additive effect when used in 
combination. 
I selected the same cell lines that were used in Chapter 4 (HRT18, RKO and 
HCT116) as these differ in their KRAS and BRAF mutational status (See section 4.1). 
First, I generated growth curves for each cell line to determine the optimal cell 
density, and the time point at which each of the cell lines achieved exponential 
growth. This was done by plating the cells at increasing densities in 96-well plates 
and growing them over a period of 7 days. Cells were harvested daily, fixed and a 
Sulforhodamine B colourimetric assay was performed to determine cell viability. 
Plates were read with a spectrophotometer and absorbance values determined at 
540nm, were used to generate growth curves for each cell lines (Figure 6.1). I then 
proceeded to establish the EC50 values of each drug in each cell line. Cells were 
plated at optimal density and allowed to grow until exponential growth was achieved 
then treated with increasing concentrations of AZD6244 or aspirin for 72h. Again, a 
sulforhodamine B assay was performed to determine cell viability. Absorbance 
values were then used to generate dose response curves and calculate EC50 values 
using Prism software. 
 Based on these data, cells were plated, left until they were growing 
exponentially then treated with 0-25mM aspirin and 0-135µM AZD6244 
individually and in combinations, for a period of 72h. Six experimental repeats were 









Figure 6.1: Growth curves for RKO, HRT18 and HCT116 cells. Cells were 
plated at increasing densities (250 to 2500 cells per well) in 96-well plates and 
grown for up to 7 days. Cells were harvested daily, fixed and cell viability was 
determined using a Sulforhodamine B assay. Data shows the absorbance 
values measured each day for each cell line.   
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Using Compusyn software, I was able to calculate the Combination Index (CI) values 
for each treatment option, and generate Fraction affected-Combination index (Fa-CI) 
Plots and isobolograms for each cell line (Figure 6.2). The Combination Index is 
used to quantify synergism or antagonism between two drugs, CI<1 indicates 
synergism, CI>1 indicates antagonism, and CI=1 indicates that the drugs have an 
additive effect (248). The fraction affected or Fa is the percentage of cells killed by 
the drug. Fa-CI Plots are a quick and easy graphic way to determine the nature of 
each drug combination and how it affected cell survival. Isobolograms also illustrate 
the nature of each drug combination but in a dose rather than effect orientated 
fashion, quickly providing an indication of the nature of the effects of each drug. If 
the combination data points fall on the hypothenuse an additive effect is indicated, if 
they fall on the lower left or upper right then combinations are synergistic or 
antagonistic, respectively. Classic isobolograms are generated for constant drug 
ratios while Normalised isobolograms are used for non constant drug ratios (248).  
Results show that in HRT18, HCT116 and RKO cell lines, a number of drug 
combinations tested present CI values far below 1, indicating a synergistic effect 
(Figure 6.2). This is most apparent when low concentrations of both aspirin and 
AZD6244 are combined. As non constant drug ratios were used, normalised 
isobolograms were generated. These show that, in all cell lines tested, the vast 
majority of AZD6244 and aspirin combinations used fall below the hypothenuse 
further confirming the synergistic effect of the drug combinations (Figure 6.2). High 
concentrations of AZD6244 and aspirin used individually or in combination result in 





            
             




Figure 6.2: Aspirin and AZD6244 have synergistic effect in all cell lines 
tested. Cells were treated with increasing concentrations of AZD6244 and 
aspirin, individually and in combination, for 72h. Sulforhodamine B assay was 
used to determine cell viability at the end of treatment, and Compusyn software 
was used to generate Fa-CI plots (left), and isobolograms (right) shown above. 
Fa-CI plots show that the vast majority of drug combinations, shown as dots on 
the graph, are synergistic (CI<1). These results are further illustrated by the 
normalised isobolograms where drug combination data points that fall on the 





Combinations of high concentrations of each drug have an additive rather then 
synergistic effect shown by CI=1. Therefore, no advantage is gained with these 
combinations when compared to individual effects. 
To further illustrate the synergistic effects of combination therapy with 
aspirin and AZD6244, I compared the levels of cell death caused by one drug 
individually and combined with increasing concentrations of the second drug. Again 
I found that in HRT18 and RKO cells the most advantageous combinations are the 
ones using the lowest doses of each drug (Figure 6.3). For example, in RKO cells 
treated with 0.7µM AZD6244 effects on cell death were negligible, but in cells 
treated with the same concentration of AZD6244 combined with 0.05mM aspirin, 
cell death increased to over 40%. Similarly, HRT18 cells treated with 0.45µM 
AZD6244 combined with 0.08mM aspirin showed nearly 40% increase in cell death 
when compared with cells treated with AZD6244 alone. However, in HCT116 cells 
combination of the two agents is not as advantageous. HCT116 cells are more 
sensitive to AZD6244 and therefore higher cell death rates are observed even with 
low concentrations of this agent (Figure 6.3). In all cell lines, treatment with aspirin 














Figure 6.3: Combined effect of AZD6244 and aspirin on cell viability. RKO, 
HRT18 and HCT116 cells were treated with increasing concentrations of 
AZD6244 and aspirin individually and in combination as described in Figure 6.2. 
Data shows the percentage of cell death that occurred as a result of each 
treatment regime. In HRT18 and RKO cells, treatment with combinations of the 
two agents results in a 2-fold increase in cell death when compared to 
AZD6244 alone. In HCT116 this effect is less apparent and higher doses of 
aspirin are needed in combination with AZD6244 in order to obtain a relatively 
small increase in cell death. 
182 
 
6.2 AZD6244 and aspirin combinations in tumour explants 
Having demonstrated that combinations of aspirin and AZD6244 have a 
synergistic effect in colorectal cancer cell lines, I proceeded to treat patient tumour 
explants with AZD6244 and aspirin, individually and in combination. Tumours were 
processed as in Figure 4.3 and as outlined in Chapter 4 then treated with 0, 0.1 and 
3μM AZD6244 alone or in combination with 100μM aspirin, in the presence of 
0.03% DMSO. No DMSO was added to samples treated with 100μM aspirin only 
and respective non treated controls. Data from the samples treated with AZD6244 or 
aspirin alone are included in the tumour panel outlined in Chapter 4. The number of 
samples treated with this drug combination was limited by the size of the tumours. 
However, in total, 8 tumours were treated with combinations of AZD6244 and 
aspirin. 
 
6.2.1 The presence of low doses of aspirin modifies pharmacodynamic 
response to AZD6244 
Firstly, I examined aspirin effects on AZD6244-mediated inhibition of p-
ERK1/2 using western blot analysis, followed by ImageJ quantification as outlined in 
section 4.3. I found that 100uM aspirin alone had a minimal effect on p-ERK1/2 
levels after 1h of treatment in most tumours (Figure 6.4). I also found that in all 
tumours, the presence of aspirin reduced AZD6244-mediated inhibition of p-
ERK1/2. This effect was most apparent when combinations of 0.1μM AZD6244 and 
100μM aspirin were used (Figure 6.5). These results would suggest that, in contrast 
to cell line data, the drugs are having an antagonistic effect, especially at the more 














Figure 6.4: Treatment with 100µM aspirin for 1h does not fully inhibit p-
ERK1/2 activity. Tumours were treated with 0 and 100µM aspirin for 1h and 
western blot analysis was performed as described in Figure 4.5. Data 
indicates that treatment with 100µM aspirin was not sufficient to inhibit ERK1/2 





Figure 6.5: Aspirin reduces AZD6244-induced inhibition of p-ERK1/2. 
Tumours were treated with 0, 0.1 and 3μM AZD6244 alone or in combination 
with 100µM aspirin for 1h and western blot analysis was performed to 
determine the effects of the combinations on p-ERK1/2 activity, as described 
in Figure 4.5. Western blots are shown on the right and respective blot 
intensity quantification data is shown in graphs on the left. 
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6.2.2 Aspirin can increase sensitivity to AZD6244 in a subset of tumours 
In order to establish if aspirin increased patient tumour sensitivity to 
AZD6244, despite effects on p-ERK1/2,  I quantified levels of proliferation marker 
Ki-67 and apoptosis marker active caspase-3 in samples treated with AZD6244 
individually and in combination with 100μM aspirin (as described in section 4.3).  
Using the response criteria previously established (See section 4.4) I found 
that aspirin can increase tumour sensitivity to AZD6244 in samples that show an 
intermediate response to treatment with AZD6244 alone (Table 6.1). However, 
increased sensitivity to AZD6244 by aspirin was only observed in 3 tumours, and 
even within this group, the extent to which tumours were sensitised varied between 
samples. In two tumours a dose-dependent inhibition of proliferation and increase of 
apoptosis was observed in samples treated with combinations of AZD6244 and 
aspirin. These two tumours were therefore classified as responders when treated with 
combination regimes but not with AZD6244 individually (Figure 6.6). Another 
tumour that presented intermediate response to treatment with AZD6244 alone, 
showed a drastic increase in apoptotic rates when treated with combinations of 
AZD6244 and aspirin. However, proliferation rates demonstrated only slight changes 
and therefore this tumour did not meet the criteria previously established for 
responding samples (Figure 6.7). Interestingly, I also found that one tumour that 
demonstrated a dose-dependent inhibition of proliferation and increase of apoptosis 
in response to treatment with AZD6244 alone, showed no effects on proliferation 
when treated with combinations of this agent and aspirin (Figure 6.8). This suggests 



















Table 6.1: Aspirin increases sensitivity to AZD6244 in a subset of 
tumours. Table shows the effects of treatment with AZD6244 individually and 
in combination with aspirin on proliferation and apoptosis, obtained by 
immunohistochemical analysis. Colour scheme represents the changes 
observed in the levels of these markers: Green indicates a >2-fold decrease in 
proliferation or increase in apoptosis; Yellow indicates a 2-fold (+/-20%) 
variation in the levels of Ki-67 and act. caspase-3; and Red indicates that no 
changes or an increase in proliferation and decrease in apoptosis were 
observed in these tumours. Data shows that in a subset of tumours, aspirin 
increased sensitivity to AZD6244 resulting in a more dramatic decrease of 



















Figure 6.6: Aspirin increased sensitivity to AZD6244 in tumours 
displaying intermediate response to treatment with AZD6244 alone. 
Tumours were treated with AZD6244 alone and in combination with 100µM 
aspirin. Immunohistochemistry was performed to assess the effects on 
proliferation and apoptosis, as described in Figure 4.6. One tail Student’s t 
test was used to calculate p values. Asterisk (*) indicates p≤0.05. Data shows 
that in these tumours, presence of aspirin increased sensitivity to AZD6244 
translated by decreased proliferation and increased apoptosis when 


















Figure 6.7: Combinations of AZD6244 and aspirin resulted in enhanced 
effect on apoptosis but not on proliferation. Tumour was treated with 
AZD6244 alone and in combination with 100µM aspirin. Immunohistochemistry 
was performed to assess the effects on proliferation and apoptosis, as 
described in Figure 4.6. One tail Student’s t test was used to calculate p values. 
Asterisk (*) indicates p≤0.05.  Data show that treatment with the combination 
regimes resulted in enhanced effect on apoptosis but not on proliferation. 
Addition of aspirin was not sufficient to fully increase sensitivity to AZD6244. 
Figure 6.8: Treatment with combination regimes does not enhance 
response in tumours presenting increased sensitivity to AZD6244 alone. 
Tumour was treated with AZD6244 alone and in combination with 100µM 
aspirin. Immunohistochemistry was performed to assess the effects on 
proliferation and apoptosis, as described in Figure 4.6. One tail Student’s t test 
was used to calculate p values. Asterisk (*) indicates p≤0.05.  Data show that, 




I received one tumour that was large enough to treat in triplicate with 
AZD6244 alone and in combination with aspirin. I found that there was good 
consistency between the triplicate samples for the drug combination studies in that 
all three samples showed a dose-dependent inhibition of both proliferation and 
apoptosis with combinations of AZD6244 and aspirin (Figure 6.9). These data 
contrast to those obtained when the samples were treated with AZD6244 alone (see 
section 4.4). In samples treated with AZD6244 individually, expression of 
proliferation/apoptosis was not consistent between replicates. As mentioned in 
Chapter 4, this tumour was much larger in size (>10x) than all other tumours in the 
panel, which resulted in increased heterogeneity between the fragments cultured. 
These data suggest that different areas of the same tumour can present variable 
sensitivity / resistance to treatment, but also that variability might depend on the 
agent used. These data may suggest that while tumour response to AZD6244 alone 




















Figure 6.9: AZD6244 and aspirin effects on proliferation and apoptosis in 
a patient tumour treated in triplicate. A single tumour was divided into 
multiple fragments and treated with AZD6244 alone and in combination with 
aspirin, in triplicate. Immunohistochemistry was used to determine effects on 
proliferation and apoptosis. Procedure is described in Figure 4.6. One tail 
student’s t test was used to calculate p values. Data shows that there is poor 
correlation between replicates treated with AZD6244 alone. However, good 
correlation between replicates is found in tumours treated with combinations of 
AZD6244 and aspirin, suggesting that response to these regimes is less 




 Data obtained with cell lines treated with combinations of AZD6244 and 
aspirin indicate that these drugs have synergistic effect, and this is more evident 
when low doses of both agents are used. However, greater synergism was observed 
in cell lines with intrinsic resistance to AZD6244 (RKO and HRT18) than in the 
more sensitive HCT116 cells. This suggests that different mechanisms are involved 
in the response to combination regimes and that these depend on individual 
characteristics of the cell population. Initial sensitivity to AZD6244 seems be an 
important factor in the response to combination therapy with this agent and aspirin. 
These data were very interesting and it prompted me to investigate the effect of 
AZD6244 and aspirin combinations in patient tumours.  
 Data obtained from patient tumours treated with combinations of AZD6244 
and aspirin are in agreement with that obtained with colon cancer cell lines. Tumours 
presented distinct responses to the combination regimes, and these seemed to depend 
on the tumour’s degree of sensitivity to AZD6244 alone. A small group of tumours 
showed increased sensitivity to treatment with combination therapy, suggesting that 
there is potential for this therapeutic option. However, data also indicates that 
combinations of AZD6244 and aspirin should not be used without further knowledge 
of the mechanisms involved in the response to combination regimes, and the 
individual characteristics behind differences observed between tumours.  
One molecule that might be involved in the mechanism of response to 
combinations of AZD6244 and aspirin is Cyclin D1. Increased levels of this protein 
are thought to be related with resistance to AZD6244 (114).  As aspirin causes 
Cyclin D1 degradation (135) sensitivity to AZD6244 might be increased by aspirin 
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in tumours presenting resistance to the MEK1/2 inhibitor alone. However, as 
previously mentioned, detection of this protein by western blot analysis proved 
challenging and therefore the levels of Cyclin D1 in tumours treated with 
combination regimes was not determined. 
Blocking p-ERK1/2 activity does not impede upstream kinases like KRAS 
and BRAF from becoming active, and might even result in loss of the feedback 
mechanisms that control pathway homeostasis (see Section 1.4.1) which can result in 
continuous activation of these upstream members of the pathway. It is then possible 
that, in order to bypass pathway blockage downstream, KRAS and BRAF will 
activate other targets. These targets would be PI3K and IKK which can be activated 
by RAS and RAF proteins, respectively (239, 245, 246), promoting proliferation and 
survival, and the expression of anti-apoptotic genes. Targeting multiple pathways 
simultaneously would overcome such mechanisms. The presence of aspirin might 
counterbalance PI3K pathway activation by inhibiting PI3K, Akt or mTOR (119-
121), and limit NFκB activity by promoting RelA translocation into the nucleolus 
(134). It would then be interesting to investigate if tumours that presented distinct 
responses to treatment with combinations of AZD6244 and aspirin, presented distinct 
patterns of activation of PI3K or downstream members of this pathway, or 
differential activation of IKK. It would also be interesting to investigate if nucleolar 
translocation of RelA occurred in all tumours treated with combinations of AZD6244 
and aspirin, or only in those that showed increased sensitivity to the combination. 
Interestingly, the NFκB pathway has recently been implicated in the initiation of 
colorectal cancer through activation of RelA (249).  
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The presence of mutations in KRAS and BRAF could also be involved in the 
response to combinations of AZD6244 and aspirin, by promoting activation of IKK 
and the NFκB pathway. Unfortunately, in the panel of tumours treated with 
combinations regimes, only two samples carried KRAS mutations and neither 
responded to combination treatment. However, the sample size is too small to be able 
to draw any firm conclusions. 
One tumour that I was able to treat in triplicate presented consistent results 
between replicates treated with combinations of AZD6244 and aspirin, but not with 
AZD6244 individually. This suggests that different parts of the same tumour might 
respond differently to treatment and that this might depend on the agent used. These 
data also suggests that while AZD6244 effects might be more variable, response to 
combination regimes is more robust. 
It is important to stress that aspirin is commonly and widely used in the 
treatment and prevention of a variety of diseases. The data here presented, suggests 
that patients who take aspirin regularly may present altered response to other 





























The development of an ex vivo model of human colorectal tumours proved 
challenging and time consuming, and the long term growth of explants ex vivo 
presented significant limitations. Following these shortfalls, I proceeded to 
investigate the response of patient tumour explants to acute treatment with the 
MEK1/2 inhibitor AZD6244. 
Using acute (short time point) treatments, I was able to consistently detect a 
reproducible pharmacodynamic response to AZD6244 in colorectal tumours from 
patients. This effect was evident by full inhibition of p-ERK1/2 within 1h of 
treatment with this agent, and it was observed in all tumours treated (see Figure 4.5). 
Furthermore, this effect was dose-dependent, and it was observed in two independent 
assays, western blot and RPPA analysis. Pharmacodynamic effects of treatment with 
aspirin, and combinations of this agent and AZD6244 were also observed using this 
method (see Figure 4.13 and 6.5). This suggests that an acute incubation can be 
useful to confirm the pharmacodynamic effects of drug treatment in patient tumour 
explants. Potentially, such a platform could also be used to examine the 
pharmacodynamic consequences of combination treatment strategies, helping to 
provide supporting evidence for their use in clinical development. It could, for 
example, be used to test the effects of anti-EGFR therapies in a wild type KRAS 
context, or effects of therapies that target the PI3K pathway, alone or in combination 
with AZD6244. However, it is less clear if the effects further down of pathway 
inhibition can be robustly measured using this study platform. This was investigated 
using RPPA analysis. However, I could not detect any significant changes in 
response to treatment with AZD6244 possibly due to the sensitivity of the assay or 
the choice of markers available.  
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When the phenotypic consequences of compound treatment were evaluated, 
much greater variability in response was observed. Consequently, strict classification 
criteria were required to stratify the tumours. I set stringent criteria so that tumours 
were considered sensitive to treatment only when reductions in cell proliferation and 
increases in apoptosis were observed in two separate fragments of the tumour and at 
both doses of AZD6244 tested. This minimised bias introduced by the experimental 
and analysis methods. Using these criteria, I was able to identify five tumours with 
apparently increased sensitivity to AZD6244. Analysis of the mutational status of 
KRAS and BRAF indicated that, at least in this model system, sensitivity to AZD6244 
did not fully correlate with the presence of these mutations. However, the strict 
criteria used excluded many tumours, and when the responses induced by only low 
dose AZD6244 treatment (0.1μM) were examined, a better correlation with 
sensitivity and the presence of KRAS and BRAF mutations was observed. Whilst the 
availability of explant tissue hampered the number of samples that could be analysed, 
it was possible to treat one particularly large tumour in triplicate with AZD6244 and 
a combination of AZD6244 with aspirin. Whilst monotherapy treatment revealed 
intra-tumour variability, the effects observed in combination were more consistent. 
Further work on the assay is needed to examine the intra-tumoural variability in 
response to therapy in more detail. Tumours of larger size will be required for this, 
and these will be likely to be more heterogeneous. However, testing intra-tumoural 
variability in smaller samples remains challenging.  
It has been suggested that AZD6244 effects can be enhanced by 
simultaneously targeting other pathways thought to be involved in the resistance to 
this agent. Finally, I tested response to treatment with combinations of AZD6244 and 
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aspirin, in cell lines and patient tumours, and found that these agents can have 
synergistic effect. However, sensitivity to combination regimes seemed to depend on 
sample sensitivity to AZD6244 alone. 
Unfortunately, I could not develop an ex vivo model of human colorectal 
tumours that allowed for the growth of the explants and the study of response to 
longer-term treatment with AZD6244. However, the use of collagens gels showed 
some promise and I believe that it could have been improved by the use of tissue 
slices instead of fragments. The use of multicellular tumour spheroids obtained from 
disaggregated tumours also appeared to be a promising method despite the fact that it 
required extensive characterisation to determine if original tissue architecture was 
replicated in these structures, and optimisation of the analysis methods. 
Regardless of the method used, growing tumours ex vivo is a technically 
difficult, time consuming and expensive process which might explain why these 
systems are not widely and routinely used. Ex vivo models are also limited by ethical 
issues and tissue availability; and with improvements in screening and detection of 
colorectal cancers the number and size of the tumours available is considerably 
reduced which limits the experimental options. Ideally, these platforms would be 
used together with clinical trials, so that responses observed in the lab could be 
correlated with those observed in the clinic, and validation of the method could be 
performed. However, this would require adaptation of the model system to the even 
smaller biopsy samples.  
With the cancer stem cell field rapidly evolving, and recent reports that 
demonstrate the survival promoting role of stem cell marker Lgr5 in human 
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colorectal adenoma cell lines (250), it is also likely that colorectal cancer study 
models will soon take a different direction.  
In summary, acute treatment of colorectal tumours can be used for 
pharmacodynamic readouts, but additional work is required to optimise for 
responsiveness, and robustly measure phenotypic effects. The ideal method would 
enable identification of markers of sensitivity and resistance early on in drug 
development, and contribute to the refinement of markers that could then be 
employed on diagnostic biopsies to stratify patients more widely in later trials. In 
other words, this model together with higher throughput analysis methods has the 
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